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Abstract
Chimeric antigen receptor (CAR) T cell therapy has had remarkable success targeting B cell leukemias in
human patients, but unexpected toxicities and failures in other disease demonstrate the need for more
predictive pre-clinical animal models than the murine ones currently used. Dogs develop spontaneous
malignancies similar to humans in their tissues of origin, gene expression profiles, treatments, and
disease courses, and have long been used as models for immunotherapy. I hypothesize that the
development of CAR T cell therapy for dogs with spontaneous disease and that the treatment of these
canine patients will recapitulate the observations found in human patients, and provide new insights into
the safety and efficacy of this breakthrough therapy. To achieve this, I first established methods for
growing primary canine T cells from healthy and disease-bearing donors to clinically relevant scale,
developed RNA electroporation protocols to transiently express a CAR targeting the canine tumorassociated antigen CD20, demonstrated its function in vitro, and treated a relapsed canine B cell
lymphoma patient with autologous CAR T cells as a proof of feasibility. I then developed methods to
permanently express a second-generation cCD20-8-28-ζ CAR in canine T cells using lentiviral
transduction, showed in vitro antigen-specific function and proliferation of CAR T cells, and treated four
canine B cell lymphoma patients with CAR T cells. Based on my observations from those patients, I made
iterative improvements to the T cell culture system and CAR construct, and treated a canine B cell
lymphoma patient with cCD20-8-BB-ζ CAR T cells, whose tumor cells lost target antigen expression to
avoid immune pressure. These results prove that it is not only possible to generate canine CAR T cell
therapy, but that it recapitulates observations found until now only in human patients. In addition, novel
findings regarding the recovery of T cells during ex vivo culture and the host immune response to the CAR
demonstrate that this model can already inform human medicine.
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ABSTRACT

DEVELOPMENT OF CANINE CHIMERIC ANTIGEN RECEPTOR T CELL
THERAPY FOR TREATMENT & TRANSLATION
Mohammed Kazim Panjwani
Nicola J. Mason, BVetMed, PhD, DACVIM

Chimeric antigen receptor (CAR) T cell therapy has had remarkable success targeting B
cell leukemias in human patients, but unexpected toxicities and failures in other disease
demonstrate the need for more predictive pre-clinical animal models than the murine ones
currently used. Dogs develop spontaneous malignancies similar to humans in their tissues
of origin, gene expression profiles, treatments, and disease courses, and have long been
used as models for immunotherapy. I hypothesize that the development of CAR T cell
therapy for dogs with spontaneous disease and that the treatment of these canine patients
will recapitulate the observations found in human patients, and provide new insights into
the safety and efficacy of this breakthrough therapy. To achieve this, I first established
methods for growing primary canine T cells from healthy and disease-bearing donors to
clinically relevant scale, developed RNA electroporation protocols to transiently express
a CAR targeting the canine tumor-associated antigen CD20, demonstrated its function in
vitro, and treated a relapsed canine B cell lymphoma patient with autologous CAR T cells
as a proof of feasibility. I then developed methods to permanently express a secondvi

generation cCD20-8-28-ζ CAR in canine T cells using lentiviral transduction, showed in
vitro antigen-specific function and proliferation of CAR T cells, and treated four canine B
cell lymphoma patients with CAR T cells. Based on my observations from those patients,
I made iterative improvements to the T cell culture system and CAR construct, and
treated a canine B cell lymphoma patient with cCD20-8-BB-ζ CAR T cells, whose tumor
cells lost target antigen expression to avoid immune pressure. These results prove that it
is not only possible to generate canine CAR T cell therapy, but that it recapitulates
observations found until now only in human patients. In addition, novel findings
regarding the recovery of T cells during ex vivo culture and the host immune response to
the CAR demonstrate that this model can already inform human medicine.
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CHAPTER 1: Background

This thesis pulls together various threads, including the role of T cells in protective
immunity and their mechanisms of action, the interactions between T cells and cancer,
and the various animal models and immunotherapeutic modalities that have been
generated to advance effective anti-tumor immunity. A brief review of these items is
contained within this chapter, to provide the context, rationale, and structure for this
thesis to the reader.

An Overview of the Role of T cells in the Immune System
T cells, and the cell-mediated immunity that they provide, form one arm of the adaptive
immune system. Unlike the innate immune system, which generates a rapid defense of
the host in response to pathogens based on the recognition of broad patterns and signals,
the adaptive immune system is finely-tuned in its reactions to specific antigens. There is
an initial tradeoff between speed and specificity in adaptive immunity, as the responses
originate from single cells that must multiply and mobilize to mount an effective defense,
but the beneficial outcome for the host is the development of immunological memory –
rapid, specific, and long-lasting protection. These characteristics and how they are
formed are best described through the example of T cell development and function.

1

T cells are broadly designed to recognize and counter the corruption of selfness within
the host – detecting intracellular bacterial and viral infections present within host cells,
and aiding in the removal of parasitic and extracellular infections shown to them by
antigen-presenting cells. To do this, T cells develop in the specialized organ from which
they derive their name, the thymus, where they receive signals to encourage productive
development and prevent potentially deleterious outcomes. At the heart of this is
formation of the T cell receptor (TCR), through which the T cell binds and recognizes its
cognate antigen. In order to account for all possible antigens of all possible
conformations, the recombination of V, D, and J gene segments along with the addition
of P and N nucleotides results in trillions of possible TCRs (Davis and Bjorkman, 1988).
This vast diversity of TCRs is trimmed down during development on the basis of two
major criteria: compatibility with host presentation of antigens, and non-reactivity to
host-derived antigens. The first of these steps, referred to as positive selection, is based
on recognition of the host’s major histocompatibility complexes (MHC). MHC are the
product of multiple genes, themselves among the most polymorphic in vertebrate
genetics, resulting in a near-unique barcode for the host’s cells (Robinson et al., 2015).
This surface protein displays short polypeptide sequences derived from proteins either
generated within the cell (in the case of MHC class I on all nucleated cells) or taken up
by the cells (in the case of MHC class II on specialized antigen-presenting cells), giving a
window into each nucleated cell’s processes and health. In order to receive a survival
signal and continue, the TCR of a developing T cell must be able to bind onto the host’s
MHC as displayed on the surface of thymic epithelial cells, otherwise the T cell will die
of neglect. Cells within the thymus present self-peptides on their MHC; therefore, to
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prevent the development of T cells that could attack the host, T cells that have a TCR that
binds too tightly to these MHC-peptide complexes because they recognize both the MHC
and the self-antigen are signaled to undergo apoptosis and are also eliminated in the
process known as negative selection.
This delicate balance between assuring recognition and elimination of threats harmful to
the host and avoiding pathology caused by attacking the host itself continues after
development, when the T cell is mature and has exited the thymus. T cells that are naïve
and encounter their cognate antigen for the first time must not only have a successful
TCR-MHC-peptide interaction, but must also receive a co-stimulatory signal to carry out
their effector functions and multiply (Mueller et al., 1989). Even so, the activation of the
T cells response is accompanied by negative feedback loops. These include the
upregulation of inhibitory receptors on the T cells that can dampen and prevent further
activation, and other cells in their immediate environment taking actions to protect
themselves by upregulating the corresponding ligands for these inhibitory receptors
(Linsley et al., 1991).
Upon successful activation of the T cells, they proliferate and can give rise to an array of
population subtypes such as highly functional effector cells that die off after clearance of
the infection or memory cells that persist either in the secondary lymphoid organs or in
the circulation and tissues of the host to protect against challenges from the same
pathogen. These cell fates, the fine distinctions between them and among subtypes of
their categories, and how they are generated are active areas of research. Recently
identified and relevant subtypes of T cells include naïve-like memory cells that are less
3

differentiated, and “exhausted” T cells that keep chronic infections in a stalemate without
successful clearance or memory generation (Gattinoni et al., 2011; Pauken et al., 2016).
The result of these processes and other factors is that the T cells populations of the
immune system are poised to provide a potent, robust, and flexible defense of the host
against any threats it may encounter.

The Interactions between Cancer and T cells
Perhaps the most challenging of these threats is the host’s own cells. Cancer has
shadowed the existence of multicellular organisms likely since their evolutionary origin.
That is not to say that the immune system has no role in the host’s defense against
malignancy. The concept of cancer immunosurveillance, that the immune system
eliminates the vast majority of neoplastic clones that arise over the lifespan of the host,
was proposed over a century ago, and evidence supporting this built over the following
decades as our understanding of both cancer and the immune system grew (Burnet,
1957a, b; Ehrlich, 1909). As inbred strains of mice became available and were tested for
transplant rejection and acceptance, it became clear that tumor rejection or outgrowth was
linked to the same mechanisms that rejected or accepted transplants (Billingham et al.,
1954a; Billingham et al., 1954b). Mice with genetic knockouts that prevented the
development of T cells or natural killer cells, their closely-related cytotoxic innate
counterpart, or eliminated the ability to produce or respond to their key mediators such as
IFNγ and STAT1 were more susceptible to spontaneous or induced tumor formation
4

(Kaplan et al., 1998). Additionally, humans with naturally occurring primary or acquired
immunodeficiencies are also more susceptible to a variety of malignancies due to viral
infection or impaired DNA repair (Salavoura et al., 2008). These and many other pieces
of evidence led to a model where the immune system, largely mediated by T cells,
eliminates most tumors, and those tumors that survive and thrive have adapted to its
pressures.
This model, known as immunoediting, consists of three processes: elimination,
equilibrium, and escape. Elimination of the tumor is largely described by
immunosurveillance. Cancer is a disease of genomic instability and, in the process of
transformation and subsequent mutations during proliferation, a population of
neoantigens that are recognized by the immune system as non-self are generated and
targeted. However, another consequence of this genomic instability is that there is
heterogeneity among the tumor population, and not all cells are always eliminated.
Equilibrium can be viewed as a form of microevolution, where the tumor and immune
system constantly adapt to each other’s tactical shifts until one finally gains the upper
hand – either the immune system eventually pushes the tumor back to elimination, or the
tumor progresses to escape the immune system.
To escape the immune system, cancerous cells have at their disposal the entire cellular
genome and with it the checks and balances hardwired into the immune system. Tumor
cells may lose expression of the neoantigens being targeted by the host’s T cells, and they
can also downregulate expression of MHC to render themselves effectively invisible to
the T cells. Additionally, they can downregulate ligands that provide co-stimulation to T
5

cells and upregulate ligands for inhibitory receptors on T cells. Tumor cells can also
create a hostile microenvironment for T cell activity, such as producing chemokines to
prevent migration to the tumor site, producing suppressive cytokines, and recruiting
suppressive cells such as myeloid-derived suppressor cells and anti-inflammatory
regulatory T cells. Combinations of these and other steps entrench the tumor over time
until it survives and escapes the immune response.
Thus cancer, as we know it when it finally reaches clinical notice, is a select population
that has evolved under intense survival pressure to stymie and outwit the natural immune
response.

A Brief Review of Cancer Immunotherapy Strategies
However, just as our understanding of the interactions between cancer and the immune
system has increased, so has our arsenal for augmenting a pre-existing anti-tumor
immune response or generating one de novo.
One of the earliest approved methods for augmenting anti-tumor responses is injection
with the cytokine IL-2, to amplify the proliferation of reactive T cells in the host –
including those presumably reacting to the tumor (Atkins et al., 1999). In a similar vein,
IL-12 has been used to skew the T cell response toward a more inflammatory strategy
(Atkins et al., 1997). As a logical extension of this, samples of the tumor have been
excised and treated with high doses of IL-2 ex vivo, with the expectation that the tumorinfiltrating lymphocytes present in this tissue will include tumor-specific T cells that will
6

selectively proliferate out and can then be infused back into the patient (Rosenberg et al.,
1985).
Another strategy has been to manipulate the inhibitory axis of the tumor-T cell
interaction, called checkpoint blockade. Monoclonal antibodies that block the interaction
between PD-1 and PD-L1, which would short-circuit T cell activation, as well as
antibodies blocking CTLA-4, an inhibitory receptor on T cells that also deflects and
dampens activation, have been approved (Brahmer et al., 2012; Topalian et al., 2012;
Wolchok et al., 2010). Depletion of regulatory T cells through a monoclonal antibody
against CD25 has also been approved (Rech et al., 2012). Antibodies against other
inhibitory receptors and ligands such as LAG3, TIM3, GITR, and others are all in various
stages of research and development.
These strategies have found success in melanomas, smoking-associated lung cancers,
mismatch-repair associated colon cancers, and other malignancies associated with high
mutational burden and, with it, a large number of neoantigens to be targeted by the
immune system – haystacks relatively rich with needles to find (Alexandrov et al., 2013).
Other cancers require the creation of an immune response from the beginning.
Treating cancer like any other pathogen, one strategy has been vaccination with tumor
antigens in hopes of spurring a response. The first-ever FDA-approved cell-based
therapy, outside of allogeneic hematopoietic stem cell transplants to induce graft versus
tumor effects, was sipuleucil-T (Kantoff et al., 2010); this therapy used patients’ dendritic
cells – the archetypal antigen-presenting cell – that had been grown ex vivo and loaded
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with the tumor-associated antigen prostatic acid phosphatase before re-infusion back into
the patients to induce a T cell response against the prostate cancer. More recent
technological advances have allowed identification of the patient’s unique neoantigens
and pulsing ex vivo expanded dendritic cells with these in hopes of a more specific and
immunogenic response (Carreno et al., 2015).
If anti-tumor responses cannot be elicited, they can be genetically encoded. TCRs
specific for tumor-associated antigens have been sequenced, and can be expressed in bulk
T cells from another patient to confer them with the same specificity and, ideally, antitumor effect (Clay et al., 1999). However, this method has one major hurdle that is
intrinsic to all TCRs: the MHC. These TCRs are restricted to how the peptide is presented
in the MHC of their host of origin, and the diversity of MHCs precludes widespread
applicability. Another consequence of MHC-dependence is that these transgenic TCRs,
like any other TCR, are susceptible to tumor evasion by MHC downregulation.

Review of Chimeric Antigen Receptors
To circumvent the T cell’s MHC restriction and dependence on MHC presentation – in
effect, to undo positive selection – the T cell would need to be engineered with a novel
antigen receptor combining MHC-independent antigen recognition with the TCR
signaling cascade – a chimeric antigen receptor (CAR).
The first prototype was proposed in 1989 by Gross and Eshhar, combining the
specificity-determining variable chains of an antibody to the constant chains of the TCR,
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which successfully signaled when challenged with the native antigen expressed on a cell
or even immobilized on a surface (Gross et al., 1989). While the target antigen was 2,4,6trinitrophenol (TNP), found in explosives but not pathogens, this demonstration was a
proof of concept for future constructs intended “to kill tumor or virally infected cells.” In
fact, the first design aimed for practical use was a direct fusion of CD4 with the CD3ζ
subunit of the TCR complex, using the CD4 as the antigen-binding domain through its
interactions with gp120 of HIV (Romeo and Seed, 1991). One more major innovation in
the early 1990s was the full conversion of the immunoglobulin-TCR hybrid extracellular
domain into a single chain variable fragment (scFv) that would endow the CAR designs
with a full antibody-like repertoire (Eshhar et al., 1993). The use of scFvs as the antigenbinding domain remains the most popular design to the present. As structure is function
when it comes to antigen-binding, the choice of linker, hinge, and transmembrane
domains are critical for the CAR to work, and needs to be assessed for each individual
scFv.
The intracellular, cytoplasmic signaling domains are also key – in order to synthetically
engineer a successful T cell response, one must understand how a T cell signals in the
first place. It became clear as T cell studies, both endogenous TCR and CAR-based,
moved beyond select cell lines and into primary T cells that signaling through the TCRassociated CD3 components alone is insufficient for a productive response and, in fact,
can lead to anergy and cell death. As evidence built for the important role of antigenindependent co-stimulation in normal T cell function, the best-characterized of these,
CD28, was included in a CAR construct (Finney et al., 1998). The CD28 signaling
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domain was in cis with the rest of the fusion protein, so that antigen-binding cued both
signals and bypassed the need for the target cell to express the corresponding costimulatory ligand. Other co-stimulatory receptor domains followed, including OX40,
ICOS, 4-1BB, CD27, and many others as well some of NK cells (Finney et al., 2004;
Milone et al., 2009; Song et al., 2012). This step in the evolution of CAR design was a
critical leap, permitting its signaling to drive primary T cell function and expansion
similar to natural T cell response. It is these second-generation CAR T cells, using CD28
and 4-1BB co-stimulatory domains, which led to the partial and complete remissions of B
cell malignancies in human patients reported in 2010 and 2011 (Kalos et al., 2011;
Kochenderfer et al., 2010; Porter et al., 2011).
At the beginning of this thesis work in 2012, ClinicalTrials.gov listed 21 active trials
using CAR T cells as a therapeutic agent. As of 2017, there are at least 170 listed. Much
has been learnt in the course of these years, both in patients and in vitro. Within CAR
design itself, it has been found that not all co-stimulation is equal; the use of CD28 can
lead to rapid proliferation and robust early function of the CAR T cells, but the use of 41BB can lead to longer in vivo persistence (Milone et al., 2009). These differences can be
exacerbated by the scFv used – one targeting the tumor-associated disialoganglioside
GD2 was found to self-ligate, resulting in tonic signaling which, depending on the costimulation used, could lead to self-exhaustion (Long et al., 2015). Another potential
consequence of the scFv derives from its species of origin – the CAR is a novel protein
being introduced into the host, and if a component is foreign, such as a murine-based
scFv, it can be immunogenic and result in anti-CAR antibody responses (Maus et al.,
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2013). Beyond design, the nature of the T cells themselves being generated are still being
explored, with the merits of effector memory and central memory cell types being
weighed and attempts to skew the T cell population culture one way or the other before
infusion and to identify an ideal ratio of CD4+ and CD8+ T cells are being made
(Sommermeyer et al., 2015; Turtle et al., 2016). Within the patient, pre-conditioning with
chemotherapy to reduce tumor burden and carve out a homeostatic nice for the incoming
CAR T cells has been found to have significant effects on treatment outcomes and side
effects (Turtle et al., 2016). This may be related to the finding that one of the most
significant prognostic factors for treatment outcome is in vivo expansion of the CAR T
cells after infusion. The chief non-antigen-directed adverse effect observed so far has
been cytokine release syndrome (CRS), a massive inflammatory positive feedback loop
in which IL-6 seems to be the lynchpin and can be lethal (Grupp et al., 2013); it is still
unclear whether the early stages of this are necessary for tumor clearance, or if it is a side
effect that can be decoupled from efficacy and avoided altogether. On the other hand, it
has been found that CAR T cells remain susceptible to many of the mechanisms for T cell
suppression, such as PD-1 interactions especially in solid tumor environments (Li, 2016;
Moon et al., 2014). Even before they become CAR T cells, T cells from heavily pretreated patients with advanced disease may already be suboptimal for making a
therapeutic cell product, and these patients may benefit from CAR T cells derived from a
healthy, allogeneic donor if the effects of graft versus host disease (GVHD) can be
avoided (Fraietta et al., 2016; Porter et al., 2015).

11

This first generation of successful CAR T cell therapy will need to be followed with
advances in knowledge and technology to extend effective and safe treatment to a wider
affected population. Innovations in our understanding of T cell differentiation and the
consequences of CAR design will guide more precisely tailored therapies, and
combinations with other experimental and approved agents such as checkpoint inhibitors
will enhance CAR T cell activity beyond its current reaches. Next-generation geneediting has opened the door to even more possibilities, such as the deletion altogether of
inhibitory genes, the insertion of suicide-gene cassettes for halting therapy post-infusion,
and elimination of the TCR and MHC on CAR T cells for potentially safer allogeneic
transfer. This diverse array of new options for potential CAR therapies will first need to
be tested in pre-clinical animal models for efficacy and safety before advancing into
clinical trials for humans.

Animal Models for Immunotherapy
Mouse models have been a favorite of the immunologist’s toolbox for decades. Given
their genetic flexibility, with an abundance of gene knockouts already available or easily
generated, they can be readily adapted to precise and elegant studies for basic and
mechanistic insights into the immune system. Combined with their small size, rapid
breeding, and relatively low maintenance that add up to inexpensive overhead costs, it is
easy to understand why the use of mouse models for studying immunotherapies was a
natural first step. However, the same factors that gave mouse models strength for
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studying immunology are an Achilles’s Heel when it comes to testing cancer
immunotherapy: the lack of background genetic diversity makes spontaneous malignancy
either uncommon, or unnaturally homogenous.
Several models for tumor-bearing mice have been developed in attempts to address this.
For tumor induction, the chemical carcinogen methylcholanthrene has been widely used
to identify genetic factors that prevent progression from DNA damage to overt disease
but has found little ground in the field of treating already-formed tumors. Some mouse
models have been bred to express oncogenes and spontaneously develop tumors, and
some of them have been designed to even recapitulate common genetic lesions found in
human disease; mice with K-ras G12D and p53 R172H mutations under a pancreatic
progenitor-specific promoter develop a pancreatic adenocarcinoma strikingly similar to
the human cancer, including histology and metastatic sites (Hingorani et al., 2005).
However, the genetic background of the mice developing the cancer, and the cancer
itself, lacks the genetic variegation that characterizes – and poses such a challenge in –
humans.
In order to better model human tumors and the response of human T cells, transplants of
both were attempted in mice. However, this xenograft of human tissues requires a critical
step that would limit the findings that could be derived from the model: the mouse’s own
immune system needs to be crippled so that it would not reject the tumor or the T cells. In
a sense, the host’s own immunoediting is lost. Many insights could still be gained from
this chimeric system – trafficking of the T cells to the tumor site, tumor regression or
progression, exhaustion within solid tumors, short-term persistence of the T cells.
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However, interactions between the host and the tumor and between the host and the T
cells are limited across the species barrier. A transplanted tumor has not undergone the
evolutions elicited by the immune pressures a naturally-occurring malignancy has within
its host, and has not established a similar immunosuppressive niche through interactions
with host immune cells. Transformed cell lines do not have competing subpopulations
that have the potential to escape the immune response or to form a therapy-resistant
relapse later on. In fact, the transplanted human tumor will express the human tumorassociated antigen being targeted, so there is little possibility of observing off-tumor ontarget toxicity against normal tissues expressing the antigen. The T cells are not derived
from a host that has undergone extensive prior chemotherapy, and therefore been hobbled
by the chemotherapy and previous interactions with the tumor. The cross-talk between
the T cells and other immune cells of the host is cut short by the species barrier.
Some of the most surprising findings during the CAR T cell clinical trials in human
patients were surprising precisely because they were not predicted in the mouse models
that preceded them and, in fact, could not have been. Targeting human carboxyanhydrase-IX on renal cell carcinomas or human Her2 on mammary carcinomas
transplanted into mice would not have predicted dangerous and even lethal toxicity in
response to normal antigen expression in the human bile duct epithelium or lung cells
(Lamers et al., 2013; Morgan et al., 2010). A mouse would not generate antibodies
against a murine scFv, especially mice that are deficient in B cells to allow tumor
transplantation, yet humans do. The cross-reactivity of cytokines produced by human
CAR T cells with the host cells of the mouse they have been injected into are limited,
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therefore an inflammatory positive feedback loop leading to something like CRS would
be hindered. Immunodeficient mice would not be pre-conditioned with chemotherapy as
they are already absent of lymphocytes, and therefore cannot model the effects on
homeostatic proliferation and engraftment of infused CAR T cells. Finally, mouse models
rarely last long enough to account for CAR T cell memory formation and years-long
persistence, along with post-remission relapses and tumor immune-editing, both due to
the lifespan of the mice as well as eventual GVHD of the human T cells against the host
mouse tissues.
To model CAR T cell therapy, and cancer immunotherapy as a whole, a better animal
model is required. While non-human primates are genetically as close as one gets to
humans, malignancy is still rare, and they inhabit very different environments from
human patients. Combined with the fact that they are prohibitively expensive for larger
studies, along with ethical concerns about using closely related species for
experimentation, it is unlikely that they will be the bridge to human clinical trials. An
ideal pre-clinical animal model would develop spontaneous malignancies that occur at a
comparable or higher incidence than humans, have similar genetic bases, and are treated
with the same conventional therapies. They would be outbred to account for genetic
variation, and a large number of them readily available so that a study could be powered
to look beyond the background noise of the genetic variation, as well as share the same
environment as humans so as to have the same exposure risk factors. In other words, the
ideal pre-clinical animal model is actual cancer patients – just not human ones.
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An Overview of the Canine “Model” of Cancer
Canines are believed to be the first species domesticated by humans, with their remains
buried alongside each other as early as over 14,000 years ago (Morey, 2006). Millennia
of intentional co-existence between our species had resulted in unique opportunities for
insight into genetic diseases, especially cancer. Unlike lab mice, dogs are a relatively
outbred population that live alongside humans, but also have breed dispositions to
particular malignancies due to selective breeding in recent centuries, accounting for both
genetic and environmental risk factors.
In fact, canines are estimated to have roughly ten times the incidence of cancer compared
to humans, 5,300 diagnoses per 100,000 compared to 500 (Schiffman and Breen, 2015).
In lymphoma, especially, there is no dearth of canine cases, with estimates of up to
250,000 new cases in the U.S. in 2014. The pathology is similar enough to human disease
that the same WHO criteria are used for classification, and a regimen of
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy is
used as first-line induction therapy for both species. B cell non-Hodgkin’s lymphoma, the
predominant type in both canines and humans, shares genetic similarities as well across
species: divergence into activated B cell and germinal center B cell subtypes, NFκB and
BCR signaling pathway activations, and IgH locus mutational activity, among others
(Modiano et al., 2007; Richards et al., 2013). B cell lymphoma is an attractive target
disease since it occupies the transitional space between leukemias, for which CAR T cell
therapy has been largely successful, and other non-hematological solid tumors, where
CAR T cell therapy has struggled to achieve lasting remissions. Canine cancer,
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particularly B cell lymphoma, is an excellent model for human disease, and therefore an
excellent candidate for modeling for cancer immunotherapy as well.
Canines have a long history of being used as animal models for humans even outside of
cancer immunotherapy. Beagles have been a popular breed to assess drug toxicology ever
since the FDA required proof of safety from drug manufacturers in the early 1960s.
Within the cancer field, the very first attempt at cell-based therapy – bone marrow
transplantation for the treatment of leukemia – was grounded in work done by E. Donnall
Thomas and Rainer Storb ranging back into the late 1950s performing transfers among
canine littermates (Ferrebee et al., 1958; Storb et al., 1967). This work in canines formed
a large part of the basis for pre-conditioning regimens of chemotherapy and irradiation,
mechanisms of GVHD and GVL, and transplant biology in humans.
More recent immunomodulatory cancer therapies, such as STAT3 signaling inhibitors
and vaccination with tumor antigen-expressing Listeria, are also being tested in dogs with
spontaneous malignancies as a model for human diseases (Couto et al., 2012; Mason et
al., 2016). Infusion of ex vivo expanded autologous T cells back into canine B cell
lymphoma patients has also been attempted (O'Connor et al., 2012).
The use of canine patients as a pre-clinical model for cancer immunotherapy has gained
increasing interest and support in recent years, from experts in both the human CAR T
cell and veterinary immunotherapy fields, as well as the Institute of Medicine’s National
Cancer Policy Forum (Kalos and June, 2013; Mata et al., 2014; National Cancer Policy et
al., 2015).
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Rationale and Structure of this Thesis
CAR T cell therapy is a living drug – it reproduces, metabolizes, adapts, differentiates,
engrafts, kills, and dies. The true test of its risks and benefits, its limitations and potential,
is in action in a system as complex and realistic as the challenge it will eventually face
inside humans. Canine patients, which spontaneously develop malignancies similar to
ours in genetics, pathology, treatment, and outcomes, are the closest model we have to
human cancer patients. The development of CAR T cell therapy for canine patients will
allow more accurate and predictive testing of the next generation of CAR T cell
therapies, which in turn will lead to safer and more efficacious treatment of both humans
and their millennia-long companions.
This thesis is structured into six parts. This first chapter has provided the background and
rationale for this thesis. The second chapter focuses on efforts to make treating canine
patients with lymphoma feasible. This involves the development of early-stage methods
and reagents to grow canine T cells ex vivo and their characterization, the validation of
mRNA electroporation as a strategy for efficiently genetically modifying primary canine
T cells to express a CAR, in vitro testing of canine B cell-targeting CAR constructs, and
concludes with the first-ever use of CAR T cells to treat a canine patient in a veterinary
clinical trial and the observations gained from this. The third chapter focuses on the
development of methods to permanently express a second-generation CD28-containing
CAR construct gene in primary canine T cells through transduction with lentivirus, and
clinical and immunological observations from four canine B cell lymphoma patients
treated with this therapy. The fourth chapter focuses on following up on these findings in
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the patients to develop improvements at each step in the production process to make CAR
T cell therapy in canine patients more effective. This involves modifications to the
culture system and the CAR construct itself to enhance growth and the formation of
memory cells, and tracking clinical and immunological outcomes in a canine lymphoma
patient treated with CAR T cells grown in these conditions and expressing a 4-1BBcontaining construct. The fifth chapter consists of a discussion of the work and its
broader implications in the context of the field, as well as suggestions for future
directions. This is followed by a chapter describing the materials and methods designed
and used in these experiments and studies, as well as a bibliography of the cited
references throughout the thesis.
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CHAPTER 2: Establishing the Feasibility of CD20-Targeted CAR T Cell Therapy
in Canine Patients with Spontaneous B Cell Lymphoma

Abstract
While murine models are widely used for CAR T cell therapy, they are inadequate in
modeling the complexities of human disease and in predicting safety and efficacy.
Therefore, we set out to develop a full-cycle system – from initial blood collection to
patient infusion and monitoring – to evaluate CAR T cell therapies in canines with
spontaneous malignancies. First, we developed physiological methods to expand primary
canine T cells ex vivo to a clinically relevant scale. Then, we expressed a functional firstgeneration canine CD20-targeting CAR construct transiently. Finally, we treated a canine
patient with relapsed B cell lymphoma to demonstrate safety and beginning-to-end
feasibility. These methods and findings lay the groundwork for future studies that use a
permanently expressed second-generation CAR construct, as described in Chapter 3.

Introduction
CAR T cell therapy has demonstrated extraordinary success against particular
hematological cancers, especially B cell leukemias (Grupp et al., 2013; June, 2014; Porter
et al., 2015; Porter et al., 2011). However, its advances have been largely limited in solid
tumors. One reason is that there is a paucity of tumor-associated antigens that are both
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safe and effective beyond the B cell field. While CD19 is expressed on both malignant
and healthy B cells, B cell aplasia is considered an acceptable organ toxicity and can be
mitigated by intravenous immunoglobulin infusions into patients. This stands in contrast
to unintended pulmonary damage from Her2-targeting which can be lethal (Morgan et
al., 2010). Another is that the tumor microenvironment is suppressive in a way that
circulating malignant cells are not, and CAR T cells can be suppressed and become
hypofunctional in these solid tumors (Beatty et al., 2014; Caruana et al., 2015; Chen et
al., 2013; Lo et al., 2015; Moon et al., 2014; Textor et al., 2014). Other factors have
hindered progress, such as the development of antibodies against the murine scFv of the
CAR, or poor expansion of patient T cells ex vivo to make a product or in vivo after
infusion (Fraietta et al., 2016; Maus et al., 2013; Porter et al., 2015). Even in the best case
scenarios, where CD19 CAR T cell therapy has led to complete remissions, CRS and
unexplained neurotoxicity remain concerning (Grupp, 2016; Kalos et al., 2011; Porter et
al., 2011). None of these issues were predicted in the mouse models of CAR T cell
therapy, relying on immunodeficient mice transplanted with xenograft tumors, nor could
they have addressed them. Targeting human antigens on human tumors inside a host
mouse will not demonstrate off-site toxicity, as there is no normal tissue distribution of
human antigens within the mouse (Lamers et al., 2013; Linette et al., 2013; Morgan et al.,
2013; Morgan et al., 2010). Immunodeficient mice will not generate antibodies against
murine components of the CAR, nor will they respond to human cytokines produced
from human CAR T cells for observation of CRS.
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New generations of CAR T cell therapies are in the process of in vitro and preclinical
testing in the same mouse models that have failed to predict safety and efficacy before.
Rheostatic recognition of antigen levels, ectopic production of pro-inflammatory and
proliferative cytokines as well as chemokine receptors to aid trafficking to the tumor site,
switch receptors to convert suppressive signals into activating ones, suicide genes as a
safety switch, and TCR and MHC ablation for allogeneic therapy are but a few options
currently being explored (Ankri et al., 2013; Di Stasi et al., 2009; Fedorov et al., 2013;
Hoyos et al., 2010; Lanitis et al., 2013; Straathof et al., 2005). However, in order for
preclinical testing to have any predictive value, it needs to be done in an animal model
that has spontaneous, naturally-occurring malignancies with significant similarities to
human disease. Canines are a well-established model for human cancers, especially B cell
lymphoma (Breen and Modiano, 2008; Ito et al., 2014; Marconato et al., 2013; Schiffman
and Breen, 2015). Therefore, we believed that they would make an excellent model for
CAR T cell therapy as well.
In order to make modeling CAR T cell therapy in dogs feasible, we would need to
establish methods for growing primary canine T cells ex vivo to a large scale, design and
validate a CAR construct that targets a canine tumor-associated antigen, genetically
modify primary canine T cells to successfully express this CAR construct, and
demonstrate that these canine CAR T cells have antigen-specific function. For each of
these requirements, we sought as best we could to parallel the standards used in human
clinical trials at the time, generating and adapting reagents and protocols as necessary due
to the limited resources and knowledge available for canine T cell immunology. At the
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end of this chapter, we provide the treatment of a canine patient with relapsed B cell
lymphoma with autologous CAR T cells as a proof-of-concept.

Results
Expansion of Primary Canine T Cells using Stimulation through CD3 & CD28
At the time of this work, use of the mitogenic lectins phytohemaglutinin and
concanavalin A (ConA) or plate-bound agonistic anti-canine CD3 antibody were standard
methodology for the short-term stimulation of canine lymphocytes in vitro (Graves et al.,
2011; Kato et al., 2007). As robust expansion of these cells is necessary for eventual
clinical applications, we turned to methods that are used for human T cell adoptive
immunotherapy. Expansion of human T cells has been achieved ex vivo using a
combination of CD3 and CD28 stimulation, using agonistic antibodies against them
conjugated to beads or loaded onto K562 cells expressing CD32/CD64 (Levine et al.,
1997; Levine et al., 1998; Maus et al., 2002; Suhoski et al., 2007). Therefore, we
evaluated different expansion methods to determine if this combination of signals would
elicit robust activation and proliferation of primary canine T cells. Freshly isolated,
CFSE-labeled canine peripheral blood mononuclear cells (PBMCs) from healthy donors
were stimulated with ConA alone (ConA), beads conjugated with agonistic anti-canine
CD3 and anti-canine CD28 antibodies (Beads), or anti-canine CD3 antibody-loaded
K562 cells transduced to express human CD32 and canine CD86 (artificial antigen
presenting cell (aAPC) stimulation), or left unstimulated as a control. All three stimuli
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induced lymphocyte division within 6 days of culture, but aAPC stimulation resulted in
the greatest T cell division (Figure 2.1a) and cell expansion (5.8 ± 1.0-fold) compared
with Beads (1.7 ± 0.8-fold) and ConA (0.4 ± 0.2-fold) (Figure 2.1b,c). Additionally, cells
from all donors expanded in response to aAPCs, despite the inability of half the donor
PBMCs to expand in response to Beads (Figure 2.1a, bottom, and Figure 2.1c),
demonstrating that aAPCs consistently support largest expansion of primary canine T
cells ex vivo.

Supplementation with rhIL-2 & rhIL-21 Enhances Canine T Cell Expansion
The addition of recombinant human IL-2 (rhIL-2) and IL-21 (rhIL-21) enhances human T
cell proliferation and preferentially expands the CD8+ subset, respectively (Bucher et al.,
2009). Additional evidence from a contemporary publication suggested a similar effect
for rhIL-21 on primary canine T cells (O'Connor et al., 2012). In order to determine the
effects of these cytokines on ex vivo canine T cell expansion in our aAPC system, we
stimulated enriched peripheral blood lymphocytes (PBLs) from healthy dogs with aAPCs
in the presence of rhIL-2 and rhIL-21. Addition of rhIL-2, alone or in combination with
rhIL-21, resulted in a dramatic increase in T cell expansion 2 weeks after stimulation
(31.0 ± 4.0-fold for no cytokines, 229.1 ± 31.2-fold for rhIL-2, 41.4 ± 3.6-fold for no
rhIL-21, 212.8 ± 39.1-fold for rhIL-2 + rhIL-21; Figure 2.2a). Quantitative reverse
transcriptase-polymerase chain reaction (qRT-PCR) showed that expression of granzyme
B was increased in cultures receiving rhIL-21, either alone or in combination with rhIL-2
(0.5 ± 0.2-fold for rhIL-2, 17.9 ± 9.8-fold for rhIL-21, 6.0 ± 1.0-fold for rhIL-2 + rhIL24

21, compared to no cytokines; Figure 2.2b). Flow cytometric analysis showed that, while
all conditions resulted in an increase in CD8+ frequency and decrease in CD4+ frequency
compared with baseline, this increase this increase in CD8+ frequency was greatest in
cultures containing rhIL-21 (Figure 2.2c).

Characterization of ex vivo Expanded Canine T Cell Product
Having developed a method to expand a suitable number of primary canine T cells for
transfer in vivo, we then set out characterize the population shift that occurs from initial
PBL culture to final cell product two weeks later. We stimulated PBLs from five healthy
canine donors using anti-canine CD3 antibody-loaded aAPCs and supplemented with
rhIL-2 and rhIL-21. Characterization of peripheral T subsets in enriched PBLs from five
healthy dogs at baseline revealed ~2:1 ratio of CD4:CD8 T cells (Figure 2.3a). At the end
of the stimulation timecourse 14-15 days later, this ratio was reversed and a
predominance of CD8+ T cells was observed among the five healthy donors (Figure
2.3b). Additionally, the T cells contained a population of CD4+CD8+ double-positive
cells (Figure 2.3b), a subset that has been reported to appear in highly activated CD4 and
CD8 single positive populations (Bismarck et al., 2012). At baseline, CD79a+ B cells
represented ~40% of CD4-CD8- live lymphocytes (Figure 2.3c, left panel) and 10.6 ±
5.9% of live total lymphocytes (Figure 2.3c, right panel). At the end of culture, most B
cells and human CD45+ aAPCs were no longer detectable (Figure 2.3d). Canine T cells
from enriched PBLs could be expanded ~100-fold (Figure 2.3e, left), with an average of
6.6 population doublings over 14 days (Figure 2.3e, right). Together, these data suggest
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that the use of aAPCs loaded with anti-canine CD3 plus rhIL-2 and rhIL-21 drives robust
expansion of canine peripheral blood T cells, especially the CD8+ subset, to sufficient
numbers required for autologous T cell therapy.

Expanded Primary Canine T Cells Transiently Express cCD20-Specific CAR Following
mRNA Electroporation
The majority of human CAR T cell therapy success has been in the field of B cell
malignancies, targeting the pan-B cell antigen CD19. There is no commercially available
validated anti-canine CD19 antibody. Four anti-human CD19 scFvs were tested for crossreactivity by cloning them into CAR constructs that were then expressed in human T
cells; these human CAR T cells were challenged with canine CD19-expressing CLBL-1
cells or human CD19-expressing K562 cells in a cytotoxicity assay. While activity
against human CD19 was confirmed, none of the four constructs showed specific activity
compared to non-transduced human T cells against canine CD19-expressing CLBL-1
cells (Figure 2.4). The B cell antigen CD20 is expressed on all canine B cell lymphomas
in published reports (Ito et al., 2015; Nadler et al., 1981). Using a scFv against canine
CD20 (cCD20), we designed first-generation CAR constructs using a human CD3ζ
intracellular signaling domain targeting cCD20 or human CD19 (hCD19) as a negative
control (Figure 2.5a). We chose human CD3ζ due to its long history of validation and use
in the CAR field, and with the expectation that it would signal in canine T cells due to
84% protein identity within the intracellular domain. These constructs were cloned into
RNA vectors; electroporation of CAR-encoding mRNA has led to highly efficient
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expression in primary human T cells, and would bypass any species-specific barrier for
retroviral or lentiviral transduction at the steps of viral entry, post-entry processing,
genomic integration, and host cell transcription. Additionally, mRNA electroporation
leads to transient expression in humans, creating a built-in safety mechanism when
moving into first-in-canine in vivo studies (Schutsky et al., 2015; Zhao et al., 2010). We
chose a first-generation CAR design since many of the benefits of second-generation
constructs – enhanced proliferation, cytokine production, in vivo persistence – are moot
in the scenario where daughter cells no longer express the CAR.
To optimize mRNA electroporation of primary canine T cells, ex vivo expanded T cells
were electroporated with various voltages, pulse lengths, and amounts of mRNA (Figure
2.5b-d). The greatest transfection efficiency and viability was achieved using 500 volts
(Figure 2.5b). Longer pulse duration led to reduced viability without a dramatic increase
in CAR surface expression (Figure 2.5c). The highest transfection efficiency was
achieved using 2 μg CAR mRNA/106 T cells (Figure 2.5d); however, the minor increase
in CAR surface expression compared with 1 μg CAR mRNA/106 T cells did not justify
doubling the amount of mRNA used for large scale CAR T cell production.
The cCD20-ζ CAR was highly expressed on the surface of both canine CD4+ and CD8+
T cells 24 hours post-electroporation (Figure 2.6a). We observed a gradual reduction in
both cCD19-ζ and cCD20-ζ CAR frequency (Figure 2.6b,c) over 14 days, confirming
transient surface expression of the CAR by T cells after electroporation. Although
transient, high frequency of cCD20-ζ CAR expression were consistently observed in
expanded T cells from multiple canine donors 24 hours post-electroporation (Figure
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2.6d). We did consistently observe that the loss of surface expression of the CD19-CAR
was more rapid than that of the cCD20-CAR, suggesting that this finding is constructdependent. Given that there was no measureable difference in mRNA quality between the
two constructs (260nm/280nm spectrophotometer readings of 2.20 and 2.22, and
260nm/230nm spectrophotometer readings of 2.46 and 2.36 for hCD19-CAR and cCD20CAR mRNA, respectively, and Figure 2.7), we hypothesize that the hCD19-CAR mRNA
is less efficiently translated, more rapidly degraded, or of an inferior quality that has not
been detected by standard methods.

Primary Canine CAR T Cells Demonstrate Potent Effector Function in vitro
Our next step was to determine if canine T cells transiently redirected with CAR mRNA
possess antigen-specific, CAR-mediated effector functions against cCD20+ targets. First,
we validated surface cCD20 expression on the target cell lines. Murine 3T3 and human
K562 cells engineered to express cCD20 (3T3.cCD20 and K562.cCD20, respectively),
but not their parental cell lines, specifically expressed cCD20 (Figure 2.8a). The canine
malignant B cell lines GL-1 and 17–71 do not express cCD20 (Figure 2.8b). However,
CLBL-1, a canine B cell lymphoma line, showed high level surface expression of cCD20
antigen (Figure 2.8b), beyond that of generated target cell lines. To determine antigenspecific cytokine production, we next co-cultured target cells with cCD20-ζ or hCD19-ζ
CAR T cells 24 hours after electroporation with mRNA CAR vectors (Figure 2.8c,d).
cCD20-ζ CAR T cells specifically secreted IFNγ in response cCD20+, but not cCD20-,
cell targets. Control hCD19-ζ CAR T cells did not produce IFNγ in response to the
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cCD20+ cell lines, but specifically recognized the hCD19+ target cell line, K562.hCD19
(Figure 2.8c). As effective T cell-mediated anti-tumor activity is dependent upon
cytotoxic T cell function, canine CAR T cells were evaluated for antigen-specific
cytolytic activity. hCD19-ζ CAR T cells specifically lysed the BxPC-3.hCD19 human
cell line (Figure 2.8d). cCD20-ζ CAR T cells demonstrated antigen-specific lysis of
cCD20+ 3T3.cCD20 and CLBL-1 cell lines, but not of cCD20- 3T3 or GL-1 cell lines
(Figure 2.8d). Together, these results demonstrate that canine CAR T cells exhibit CARmediated, antigen-specific IFNγ production and cytolytic activity.

Feasibility of CAR T Cell Production from a Canine Cancer Patient for in vivo
therapeutic use
Having shown high-efficiency transfection and CAR-mediated effector function of
cCD20-ζ CAR T cells generated from healthy dogs in vitro, we investigated the
feasibility of CAR T cell production for therapeutic use in a privately-owned dog with
relapsed spontaneous B cell lymphoma. Patient 434-001 presented with relapsed B cell
lymphoma 1 month after finishing CHOP-based chemotherapy for the treatment of stage
IIIa, multicentric lymphoma. At relapse, the dog was treated with a single dose of Lasparaginase and referred for CAR T cell therapy. At initial presentation, the dog was
asymptomatic and clinical disease was limited to mild, bilateral submandibular
lymphadenopathy. Routine bloodwork showed no significant abnormalities. Flow
cytometry indicated that only 6% of leukocytes within the therapy target node were
CD79a+cCD20+ B cells (Figure 2.9a, left). After 2 weeks, 1 day prior to the first T cell
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infusion, the submandibular lymph nodes had enlarged, and cytology confirmed the
return of an aggressive B cell lymphoma (data not shown). Flow cytometry revealed that
86% of the cells in the therapy target node were now CD79a+cCD20+ B cells (Figure
2.9a, right).
Starting at day -16 relative to first T cell infusion, three peripheral blood collections were
drawn a week apart to generate three separate infusion products (Figure 2.10). PBLs
consisted of a normal 2:1 ratio of CD4:CD8 T cells at baseline (Figure 2.9b, left).
Following aAPC stimulation, expanded cell products contained a predominance of CD8+
cells (Figure 2.9b, right), and underwent between 5 and 7 population doublings,
providing ~109 cells per infusion product (Figure 2.9c). Overall, PBL preparations
underwent 34-, 162-, and 120-fold expansions for infusion products #1, #2, and #3,
respectively (Figure 2.9d).
At day 14 post-stimulation, expanded canine patient T cells were electroporated with
cCD20-ζ CAR mRNA, resulting in ~90% surface expression of CAR in both CD4+ and
CD8+ T cells (Figure 2.11a). Parallel electroporations with hCD19-ζ and cCD20-ζ CAR
vectors were also performed to evaluate the duration of CAR expression and antigenspecific effector function of T cells expanded from this lymphoma patient in vitro. Both
hCD19-ζ and cCD20-ζ CARs were highly expressed (>90%) 24 hours postelectroporation, and their surface expression gradually decreased over 14 days (Figure
2.11b,c). We also performed CAR-mediated cytokine production and cytolytic assays to
determine the functional capacity of the redirected T cells. Patient cCD20-ζ CAR T cells
co-cultured with target cells secreted IFNγ in response to all cCD20+ cell lines, (Figure
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2.11d). Minimal or no IFNγ was secreted in response to cell lines that did not express
cCD20. hCD19-ζ CAR T cells specifically produced IFNγ in response to hCD19+
targets, and did not recognize hCD19- cell lines. Similarly, patient cCD20-ζ CAR T cells
demonstrated antigen-specific lysis of cCD20+ target cells, but not of cCD20- target cells
(Figure 2.11e). Together, these data indicate that large numbers of functional, cytolytic
CAR T cells can be derived from canine patients with spontaneous lymphoma.

Assessment of Clinical Efficacy of mRNA CAR Treatment in a Canine Cancer Patient
Patient 434-001 received a total of three infusions of cCD20-ζ CAR T cells at weekly
intervals (Figure 2.10). Infusions #1 and #2 were administered intravenously (IV), and
infusion #3 was split between IV and intranodal (IN) injection. No overt, serious adverse
effects of treatment were observed. Following the third infusion, the dog developed a
mild, transient fever that resolved following fluid therapy. Within 72 hours of each
infusion, the diseased lymph node volume increased and then remained stable until the
next infusion (Figure 2.12a). Flow cytometric evaluation of the target lymph node at 72
hours after each infusion revealed a modest reduction in CD79a+cCD20+ B cells, which
returned to pre-infusion levels by the next infusion (Figure 2.12b, left). Concomitant with
the decrease in B cell frequency, an increase in CD5+ T cell frequency was observed
following each treatment dose in the measured lymph node (Figure 2.12b, right).
Absolute counts of CD5+ T cells and CD79a+cCD20+ B cells in the peripheral blood
both increase over the 72 hours after each infusion, with the most drastic increase for
both subsets occurring after the third infusion (1.95-fold for CD5+ T cells, 4.59-fold for
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CD79a+cCD20+ B cells, Figure 2.12c). That CD5 excludes canine B cells was validated
in healthy canine peripheral blood by co-staining with the pan-B cell marker CD79a
(Figure 2.13), and co-expression has not been found in 19 canine patients with B cell
malignancies that we have screened to date for clinical trials. Molecular evidence of CAR
T cell presence in the patient’s peripheral blood was tested for by RT-PCR for the human
CD3ζ component of the CAR construct, but was not detected (Figure 2.14).

Serum Cytokine and Antibody Production Following CAR T Cell Therapy
Using cytokine bead array, we observed a 2.63-fold increase in serum levels of IFNγ 24
hours post-infusion #1, which was the largest single IV dose administered (Figure 2.15a).
This increase was confirmed by enzyme-linked immunosorbent assay (data not shown).
Since human clinical investigation with CAR T cell therapy has shown significant
toxicities associated with increased serum IL-6, we also examined serum IL-6 by
cytokine bead array (CBA) (Kalos et al., 2011; Porter et al., 2011). Serum IL-6 levels
increased 1.75-fold and 1.45-fold 24 hours following dose #1 and dose #2, respectively
(Figure 2.15b). Serum levels of IL-8, IL-10, IL-15, IL-18, and MCP-1 were also
measured on the CBA panel, and all increased within 24 hours of dose #1 (Figure 2.15cg).
In human clinical trials, patients have developed human anti-mouse immunoglobulin
antibodies and anaphylaxis upon repeat administration of CAR T cells expressing a
xenogenic murine scFv (Beatty et al., 2014; Kershaw et al., 2006; Maus et al., 2013). We
hypothesized that canine anti-mouse immunoglobulin antibodies (CAMA) may also be
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induced following multiple injections of cCD20-ζ CAR T cells. We found that serum
CAMA levels were undetectable until the time of infusion #3, and sharply rose over the
following 72 hours (Figure 2.15h), indicating that, as in humans, dogs develop antimouse immunoglobulin antibodies following repeated exposure to the murine scFv
expressed on the CAR T cell surface.
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Figure 2.1. Expansion of canine T cells varies in response to different activation
stimuli. (a) Proliferation kinetics of CFSE-labeled canine PBMC as determined by flow
cytometry, gated on lymphocytes. Two representative healthy donors are shown, one per
row. (b) Enumeration of live cells post-stimulation at each time point indicated. Data
represent mean ± SEM of four independent canine donors. (c) Calculated fold change of
total live cells at day 6 post-stimulation. Each symbol represents one of four canine
donors from independent experiments. Horizontal bars represent the mean. *p < 0.05 as
measured by Dunn's multiple comparison test following one-way analysis of variance
(ANOVA).
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Figure 2.2. Supplementation with rhIL-2 & rhIL-21 enhances canine T cell expansion.
Enriched PBL from 3 dogs were stimulated with aAPCs in the presence or absence of
cytokines. (a) Calculated fold change in 7AAD-, CD5+ T cell number at day 14 poststimulation. (b) qRT-PCR analysis of canine granzyme B (GZMB) expression at day 14
post-stimulation. Expression is compared to the no cytokine condition. *p < 0.05 as
measured by Dunn's multiple comparison test following one-way ANOVA. (c) Flow
cytometric evaluation of CD4 and CD8 subsets among live T cells (size, 7-AAD-, CD5+)
at baseline (pre-activation) and 14 days post-stimulation with aAPCs in the presence or
absence of cytokines.
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Figure 2.3. Characterization of cellular phenotype and expansion following activation
with aAPC plus rhIL-2 and rhIL-21. Flow cytometric evaluation of CD4 and CD8
expression among live lymphocytes in a representative donor and quantified in healthy
canine donors (a) pre-stimulation (n = 5) and (b) 14–15 days post-stimulation (n = 5).
Frequencies underneath bar graphs represent mean ± SEM of five healthy canine donors
from two independent experiments. (c) Flow cytometric evaluation of CD79a expression
pre-stimulation. Histogram from a representative donor, gated on CD4-CD8lymphocytes (left panel); Quantified values of CD79a+ B cells, gated on live
lymphocytes (right panel) from four healthy donors. (d) Representative histogram of
CD79a staining for B cells (left panel) 14 days post-stimulation. Populations are gated on
live, CD4- and CD8- lymphocytes. Human CD45 staining (right panel) on day 0 (gray
line) and day 14 (black line) post-stimulation. Populations are gated on live cells. (e) Fold
change (left panel) and population doublings (right panel) of canine T cells 14 days poststimulation from counts of live cells by trypan blue exclusion. Data and number indicated
represent mean ± SEM of five healthy canine donors.
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Figure 2.4. Failure of anti-human CD19 scFvs to react to a CD19-expressing canine B
cell line. Left, PCR of CLBL-1 cDNA on a 1% agarose gel. Lane 1 is a 1kb+ DNA
ladder, Lane 2 is cDNA amplified for GAPDH, Lane 3 is cDNA amplified for canine
CD19. Right, specific lysis of CLBL-1 cells by human T cells expressing first-generation
CARs containing four different anti-human CD19 scFvs, normalized to lysis by
untransduced human T cells. Data represents technical replicates from one primary
human donor. Each scFv tested in 2-3 independent experiments using different primary
human donors.
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Figure 2.5. Determination of optimal electroporation conditions for canine T cells. (a)
Schematic of canine CD20 (cCD20) and human CD19 (hCD19) CAR mRNA constructs.
Cultured canine T cells were electroporated with varying (b) voltages, (c) pulse lengths,
and (d) amounts of cCD20-ζ CAR mRNA used per 106 canine T cells. Surface CAR
expression was assessed by flow cytometry 1, 3, 5, and 7 days post-electroporation.
Viability (7AAD-) was examined by flow cytometry 24 hours post-electroporation. Data
show a representative canine donor per condition set.
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Figure 2.6. The cCD20-ζ CAR is efficiently and transiently expressed in canine T cells
after mRNA electroporation. (a) Surface expression of the cCD20-ζ CAR in CD4+ (left
panel) or CD8+ (right panel) T cells 24 hours post-electroporation. (b) Kinetics of cell
surface expression of CAR in T cells. (c) Frequencies of hCD19 or cCD20 CARtransfected T cells over time. (a-c) Representative healthy donor shown from 3 dogs
analyzed. Gray histogram indicates cells electroporated with no mRNA, black line
indicates cells electroporated with CAR mRNA. Populations are gated on live
lymphocytes. (d) Frequency of cCD20 CAR+ cells 24 hours post-electroporation in nine
healthy canine donors. Frequencies displayed under graph represent the mean ± SEM.
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Figure 2.7. Comparison of hCD19-ζ and cCD20-ζ CAR mRNA quality. 2 μg of hCD19-ζ
RNA (Lane 2) and cCD20-ζ RNA (Lane 3) run on a 1% TAE-Agarose gel alongside a
1kb+ DNA ladder (Lane 1). Bands run in the vicinity of ~850bp DNA ladder band.
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Figure 2.8. cCD20-ζ CAR T cells secrete IFNγ and lyse target cells in an antigen-specific
manner. (a-b) Expression of cCD20 on the surface of (a) murine and human or (b) canine
target cell lines. Anti-cCD20 mAb staining (open histograms) overlaid with isotype
control (gray, filled histograms) as assessed by flow cytometry. Numbers in the right,
upper corner represent signal-to-noise ratios, which were calculated using the median
fluorescence intensity (MFI) of anti-cCD20 antibody binding versus isotype control. (c)
Canine T cells electroporated with hCD19-ζ CAR, cCD20-ζ CAR, or no mRNA were cocultured with the indicated cell lines at a 1:1 effector to target (E:T) ratio. After 24 hours,
IFNγ was quantified by ELISA. Data represent mean ± SEM of two healthy canine
donors from independent experiments. (d) Canine T cells electroporated with hCD19-ζ
CAR or cCD20-ζ CAR RNA were cultured with chromium-labeled tumor cell lines at a
10:1 E:T ratio. Specific lysis was calculated after 4 hours. Data is normalized to lysis of
target cells when cultured with T cells electroporated with no RNA. Error bars represent
mean ± SEM of sextuplicate wells from three healthy canine donors.
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Figure 2.9. Generation of CAR T cell product for a canine B cell lymphoma patient. (a)
Flow cytometric evaluation of B cell frequency (CD79a) and cCD20 expression among
live lymphocytes in the target lymph node 16 days prior and 1 day prior to treatment. (b)
Flow cytometric evaluation of CD4 and CD8 populations among hCD45-, live
lymphocytes in enriched PBLs prior to stimulation (Day-15) and one day prior to
infusion (Day-1) for product #1. (c-d) Growth kinetics of all three infusion products.
Enumeration of live, canine T cells by trypan blue exclusion. (c) Fold change and (d)
population doublings over time post-stimulation. Number on graph indicates mean of
three infusions products for Patient 434-001.
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Figure 2.10. Timeline of patient treatment. Diagram depicting the PBMC isolation (Iso.),
enriched PBL stimulation (Stim.), electroporation (Electro.), infusion, and post-infusion
sample collections (hr, hour) of each dose used to treat Patient 434-001.
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Figure 2.11. The cCD20-ζ CAR is expressed and functional in canine patient T cells after
mRNA electroporation. (a) cCD20-ζ CAR expression among CD4+ and CD8+ T cells 24
hours after electroporation with cCD20-ζ CAR mRNA (empty histograms) or no mRNA
(filled gray histograms). Populations are gated on live lymphocytes. (b) Kinetics of the
expression of CAR on the cell surface of canine T cells following electroporation. (c)
MFI of CAR expression on the cell surface at the time points indicated postelectroporation. (d) 24 hours after electroporation, patient T cells were co-cultured with
the indicated cell lines at a 1:1 effector to target (E:T) ratio. IFNγ in 24 hour supernatants
was quantified by ELISA. Bar graphs represent mean ± SEM. (e) 24 hours after
electroporation with cCD20-ζ CAR mRNA or no mRNA, patient T cells were cultured
with chromium-labeled target cell lines at a 10:1 E:T ratio. Specific lysis was calculated
after 4 hours. Data is normalized to lysis of target cells when cultured with T cells
electroporated with no mRNA. Data represents mean ± SEM of sextuplicate wells.
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Figure 2.12. Effects of RNA CAR treatment in a canine B cell lymphoma patient. (a)
Volume of the target lymph node (LN), as calculated from ultrasound measurements.
Arrows indicate the time of CAR T cell infusions. (b) Flow cytometric evaluation of LN
aspirates enumerating the frequency of CD79a+cCD20+ cells (left panel) and CD5+ cells
(right panel) among live lymphocytes pre-infusion and 72 hours post-CAR T cell
infusion. (c) Absolute numbers of CD5+ (red line, left axis) and CD79a+CD20+ (blue
line, right axis) cells in the peripheral blood as calculated from flow cytometry analysis
and clinical complete blood count (CBC), arrows indicate the time of CAR T cell
infusions.
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Figure 2.13. CD5 does not label canine B cells. Representative flow staining of CD79a
and CD5 of live lymphocytes from the PBMCs of a healthy donor and a B cell lymphoma
patient.
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Figure 2.14. RT-PCR of cCD20-ζ CAR from Patient 434-001 samples. PCR amplifying
the CAR from cDNA of PBMCs and lymph node aspirate cells (prescapular and
popliteal) taken from Patient 434-001 following each infusion, run out an agarose gel
alongside 1 kb+ DNA ladder. Arrows represent expected product size, - represents
negative control (water), + represents positive control (CAR plasmid template).
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Figure 2.15. Serum levels of cytokine and anti-CAR antibodies in Patient 434-001. (a-g)
Serum levels of (a) IFNγ, (b) IL-6, (c) IL-8, (d) IL-10, (e) IL-15, (f) IL-18, and (g) MCP1 at the indicated time points for each infusion as measured by cytokine bead array
(CBA). Data represents mean of duplicate tests. (h) Serum levels of canine anti-mouse
antibody (CAMA) at the indicated time points as measured by enzyme-linked
immunosorbent assay (ELISA). Data represent means of duplicates for CBA, mean ±
SEM of triplicate wells for CAMA. Dotted line represents the lower limit of detection
(LLOD) for each assay.
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Discussion
Adapting methods from work performed previously or concurrently by others, we
generated a robust, physiological system for expanding primary canine T cells ex vivo to
a clinically relevant scale (Mata et al., 2014; O'Connor et al., 2012). Using aAPCs
modified to express a co-stimulatory ligand and loaded with agonistic anti-canine CD3
antibody along with rhIL-2 and rhIL-21 supplementation, our system provided the
classical three signals for successful T cell activation and achieved an average of 213 ±
39-fold expansion of canine T cells from the peripheral blood in 14 days – the largest
reported expansion for a single-stimulation protocol at the time (Mata et al., 2014;
O'Connor et al., 2012).
This aAPC expansion protocol is successful enough to have grown three infusion
products for Patient 434-001, who had undergone two relapses. This is particularly
interesting in light of our expansion data in response to Beads, where there is a stark
bimodal response where some healthy donors do not expand. The Beads are a
reductionist system, providing only CD3 and CD28 signals, suggesting that there is a
population or phenotype of canine T cells that are resistant to these stimuli alone and
require additional support from factors that the aAPCs provide; in fact, this may be an
issue across species, as potential subjects for human CAR T cells therapy are excluded
because their T cells do not expand ex vivo in response to anti-human CD3/CD28 beads
(Fraietta et al., 2016; Porter et al., 2015). Challenges in expanding T cells from
lymphoma patients, and potential contributions from aAPCs are explored further in
Chapter 4.
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CAR expression by mRNA in primary canine T cells was highly efficient, functional, and
transient, much like has been found in humans (Schutsky et al., 2015). Despite robust
effector activity against canine cCD20+ B cell lymphoma cells ex vivo, we observed
modest, transient anti-tumor effects after adoptive cell transfer of three doses of mRNA
cCD20-ζ CAR T cell therapy in Patient 434-001. We observed growth of a target lymph
node immediately following each intravenous CAR T cell infusion, associated with a
decrease in cCD20+ B cell frequency and increase in T cell frequency. These data
support the hypothesis that infiltrating CAR+ T cells partially account for the initial
growth of the lymph node, potentially reducing the cCD20+ B cells in the 72 hours postinfusion. Still, the transient nature of mRNA-based CAR expression may explain the
rebound effect seen prior to infusion of dose #2 and #3. The absence of CAR gene
expression in the peripheral blood by RT-PCR is unsurprising. Most template mRNA is
expected to degrade within the cells within 24 hours, and infusions were performed the
day following electroporation; the remaining CAR gene template, distributed among the
infused cells, would be diluted in the large circulating blood volume present in a 50 kg
patient infused with a relatively small number, 54-240 x 106, of redirected T cells.
Despite cCD20-specific cytokine production and cytotoxicity by cCD20-specific CAR T
cells in vitro, it is possible that the transient, in vivo effects seen here were independent of
CAR activity. Systemic infusion of autologous, polyclonal, activated T cells following
successful CHOP based chemotherapy has previously been shown to prolong
progression-free survival and overall survival in a small group of dogs, an effect that
might be associated with nonspecific immune activation, such as enhanced CD40-CD40L
interaction (O'Connor et al., 2012). Additionally, the concurrent increase in peripheral
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blood B and T cells in the 72 hours following each infusion is interesting. The increase in
T cells can be explained by the infusion products, but the increase in B cells could have
several origins. One possibility is that the frequency of B cells in the lymph nodes
decreased because they entered into circulation, perhaps in reaction to inflammation in
the lymph nodes caused by CAR T cell activity. Another possible explanation is that
these infused, activated T cells were supporting B cell expansion through CD40L
presentation after CAR expression had disappeared; however, the kinetics of the
peripheral blood B cell increase and decrease is the opposite of what one would expect in
this scenario, as the B cell population in the blood decreases when the CAR is expected
to no longer be present.
The most striking consequence of CAR T cell therapy in this patient was the development
of CAMA after the second infusion, much like has been seen in humans and
understandably unobserved so far in mouse models (Kershaw et al., 2006; Maus et al.,
2013). The recapitulation of this effect across species emphasizes the need to make CARs
less immunogenic in their host, through the use of humanized or caninized scFvs. Of
additional note is that, while human CD19-targeting CAR therapy avoids HAMA due to a
combination of lymphodepleting pre-conditioning and the ablation of B cell populations
in the host as a consequence of therapy, this canine patient developed CAMA despite also
receiving B cell targeting therapy. This suggests that B cells are able to mount a
counterattack if they survive, and that anything short of complete response may
eventually lose its gains.
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While sustained anti-tumor effect such as through a stably expressed CAR may be
necessary for significant tumor regression, the transience of mRNA CARs provides a
critical built-in safety switch and makes the platform an attractive exploratory tool
(Beatty et al., 2014; Zhao et al., 2010). With intentionally short-lived CAR expression,
we are now able to preliminarily screen therapies for safety in “first-in-dog” trials
targeting tumor-associated antigens that may also be expressed on normal host tissues.
Candidate antigens deemed safe through our mRNA CAR platform could then be
examined in stably-expressed CAR systems to assess long-term efficacy. Similarly,
mRNA CARs could be used as a short-term, but potent pre-conditioning method to
modulate the tumor microenvironment and potentiate stably-expressed CAR efficacy (Lo
et al., 2015).
Having demonstrated the feasibility of generating canine CAR T cell therapy at each step
– developing methods to expand primary canine T cells ex vivo, genetically modifying
them with CAR-encoding mRNA, demonstrating robust in vitro function of canine CAR
T cells, and treating a canine cancer patient with autologous CAR T cells (Figure 2.16) –
our next goal was to stably express a second-generation CAR in primary canine T cells
and demonstrate efficacy. The efforts to undertake these steps are described in Chapter 3.
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Figure 2.16. Translation of human CAR T cell therapy into canines. Diagram
summarizing the adaptation of key steps in CAR T cell therapy for use in canine patients.
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CHAPTER 3: Development of Permanently-Expressing cCD20-8-28-ζ Canine CAR
T Cells and Their Effects in vivo

Abstract
In order to achieve long-term tumor control and elimination, the anti-tumor agent must
continue to be present and active within the host. Success in human CAR T cell therapy
has been through the use of permanently-expressed second-generation CAR constructs,
which provide intrinsic co-stimulation and pass on the CAR gene to daughter cells,
endowing them with the same tumor-specificity. To parallel this, we generated a cCD208-28-ζ canine CAR construct and successfully expressed it in primary canine T cells
using lentivirus in vitro. These CAR T cells lysed and proliferated in an antigen-specific
manner. To determine the effects of this permanently-expressing CAR T cells in vivo, we
treated four canine patients with relapsed or refractory spontaneous B cell lymphoma. We
observed evidence of temporary local tumor control and stable disease in these patients,
and indications that T cell health may be a major factor in CAR T cell therapy efficacy.
Both of these findings parallel those in human patients, and form the foundations for
exploring ways improve canine T cell quality in Chapter 4.
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Introduction
In Chapter 2, we successfully redirected primary canine T cells with a CAR to target and
eliminate cCD20-expressing target cells, including canine B cell lymphoma cells, and
treated a canine patient as a proof-of-concept. Effects were transient, reflecting the nature
of mRNA electroporation-mediated redirection, but also demonstrated that there was no
overt toxicity as a result of targeting canine CD20 in a fully autologous system. Durable
tumor control requires long-term expression of the tumor-specific agent – the CAR. To
that end, we undertook steps to permanently express the CAR in primary canine T cells.
The use of gammaretroviruses and lentiviruses for gene transfer has been explored in
canine hematopoietic stem cells, especially in naturally-occurring models of canine Xlinked severe combined immunodeficiency (Felsburg et al., 2015; Kennedy et al., 2011).
Concerns about potential oncogenic insertion in the human field are paralleled in dogs. In
fact, use of gammaretrovirus to restore the common gamma chain in dogs has been
implicated in the development of a thymoma in one of the experimental subjects
(Kennedy et al., 2011). However, the use of retroviruses in hematopoietic stem cells,
where many proto-oncogenes are active and susceptible to integration, is different than in
mature cells, and gammaretroviruses have had a safer history in human CAR T cell trials
and in one in vitro publication transducing primary canine T cells with a CAR (Mata et
al., 2014; Scholler et al., 2012). Nevertheless, the overall greater safety profile of
lentiviruses and evidence in humans of their prolonged expression in comparison to
gammaretroviruses led us to pursue this option for permanent transduction and
expression of a CAR in primary canine T cells for therapy.
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Taking advantage of observations in basic T cell immunology as well as human CAR T
cell studies that co-stimulation is necessary for a productive T cell response, we chose to
use a second-generation CAR construct incorporating intrinsic co-stimulation. Whereas
the mRNA CAR in Chapter 2 lacked a co-stimulatory domain since CAR expression
would be lost within days, survival and proliferation of the genetically modified T cells
are advantageous when the CAR is maintained and passed onto daughter cells. CD28 and
4-1BB are the co-stimulatory receptors whose intracellular signaling domains are most
frequently used in human CAR T cell clinical trials. We use a construct including CD28
in this chapter, and a construct using 4-1BB is described in Chapter 4.
In order to generate canine CAR T cell therapy with a stably-expressed CAR, we
determined a method for transducing primary canine T cells with a lentivirus,
demonstrated that canine CAR T cells selectively expand in response to the target antigen
ex vivo, and treated four canine B cell lymphoma patients that had either relapsed or were
refractory to chemotherapy. The observations from each of these four patients form the
basis for the hypotheses tested in Chapter 4.

Results
EF-1α Promoter Results in Higher Gene Expression than CMV Promoter in Primary
Canine T Cells Transduced with Lentivirus
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To maximize the efficiency of genetic modification by lentivirus, we first compared two
commonly used promoters for human T cells, EF-1α and CMV (cytomegalovirus)
(Milone et al., 2009). Using a third-generation, self-inactivating lentivirus system where
the lentivector expressed GFP and only differed in the promoter, we infected Beadstimulated PBMCs from four healthy dogs with equal MOI of lentivirus and evaluated
GFP expression 6 days after stimulation. Expression was modest, but in all four dogs the
frequency of canine cells expressing GFP was increased after infection with the EF-1α
promoter compared to the CMV promoter (Figure 3.1a,b, 6.20 ± 0.76% vs 4.33 ± 1.09%,
respectively). The difference in the level of transgene expression among the transduced
cells was dramatically increased with the EF-1α promoter compared to the CMV
promoter (Figure 3.1c, 6053 ± 1343 vs. 686 ±198, respectively). As the EF-1α promoter
resulted in both a greater frequency of transduced cells as well as higher expression
among the transduced cells, just as in humans (Milone et al., 2009), we moved forward
with lentivectors using this promoter to express the CAR construct.

Stimulation with aAPC System Results in Canine T Cell Activation and Elimination of
aAPCs from Culture
While lentiviruses have the capability of infecting non-dividing cells, activation of the
target cell is known to enhance transduction efficiency. We characterized the activation
kinetics of primary canine T cells in the culture system we established in Chapter 2, using
aAPCs with agonistic anti-canine CD3 and rhIL-2 and rhIL-21, by measuring
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upregulation of CD25 on the cell surface. Stimulating enriched PBLs from three healthy
dogs, CD25 is rapidly upregulated, with 83% of CD5+ cells expressing CD25 1 day postculture, and at least 95% expressing CD25 on days 2-4 post-culture (Figure 3.2a).
VSV-G pseudotyped lentivirus has broad tropism, and this lentivector system has been
optimized for modifying cells of human origin, such as the aAPCs. To reduce possible
cellular competition for lentivirus in culture, we measured when the aAPCs are
eliminated from culture. Enriched PBLs from six healthy dogs over two independent
experiments were stimulated with the aAPC system, and the aAPCs were largely
eliminated by day 4 post-culture (Figure 3.2b, 3.63 ± 0.68% remaining).
The near-complete loss of aAPCs from culture coincides with the continued peak of
CD25-expressing T cells, so we selected Day 4 post-culture for infection of primary
canine T cells with lentivirus encoding the CAR construct.

Expression and Function of cCD20-28-ζ CAR in Primary Canine T Cells
A CAR construct targeting canine CD20 using the same scFv as in Chapter 2 was
designed, using the following components from N to C terminus: canine CD8α leader,
murine anti-canine CD20 scfV, canine CD8α hinge, canine CD28 transmembrane and
intracellular domain, canine CD3ζ intracellular domain (Figure 3.3a,b). This construct
was inserted into a lentivector under the EF-1α promoter that had been modified from
earlier experiments to ease cloning, referred to as pELxPS. VSV-G pseuodotyped virus
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was generated and used to infect enriched PBLs from a healthy dog 4 days post-aAPC
culture, resulting in 26.4% transduction as measured by surface expression of the CAR
(Figure 3.3c).
This construct was functional in a canine lymphoma patient’s T cells, able to lyse targets
in an antigen-specific manner; CAR T cells from this dog killed over 60% of cCD20+
target cells overnight at a 5:1 ratio of T cells to targets (1 CAR T cell per 2 target cells
based on transduction efficiency, Figure 3.3e), but did not lyse cCD20- target cells, and
non-transduced cells did not react with either target cell (Figure 3.3d, cCD20 expression
of target cells shown in Figure 2.8b).
The benefit of CAR gene integration is long-term expression of the CAR as well as
passing on of tumor-specificity to daughter CAR T cells, resulting in quasi-clonal
expansion of tumor-targeting cells. Frequency of CAR+ T cells among the canine
lymphoma patient’s T cells in culture increased during sequential challenges with
cCD20+ CLBL-1 target cells (Figure 3.3e). Calculating absolute number of CAR T cells
in culture shows a numerical expansion of these cells after each of the first two
challenges (Figure 3.3f), indicating that the increase in frequency represents a
proliferation of CAR T cells in response to antigen challenge, not just death of nontransduced T cells in culture. However, following the third challenge, the absolute
number of CAR T cells decreased but the frequency of CAR+ T cells remained similar,
suggesting an eventual limit to its proliferative capacity (Figure 3.3f).
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Summary of Clinical Trial for Canine B Cell Lymphoma Patients Treated with
Lentivirally-Transduced cCD20-8-28-ζ CAR T Cells
Having demonstrated successful transduction of primary canine T cells with a lentivirus
to express a second-generation CAR, and antigen-specific cytotoxicity and proliferation
of these canine CAR T cells, we initiated a clinical trial to investigate the use of
autologous canine T cells transduced with lentivirus encoding the cCD20-8-28-ζ CAR in
canine patients with spontaneous B cell lymphoma. The goal of this trial was to assess
safety of CAR T cell therapy on an intermediate to long-term basis, clinical efficacy, and
signs of CAR T cell activity and persistence. In addition to changes in tumor size and
patient health, we examined the T and B cell populations in the peripheral blood and
lymph node by flow cytometry. In particular, we looked for CD4+ and CD8+ frequency
among T cells, as well as CD28 expression among CD4+ and CD8+ T cells. The split
between Bead-responders and non-responders in Chapter 2 (Figure 2.1c) led us to
consider that the ability of T cells to respond to stimulation through endogenous CD28
may be indicative of in vivo responses. The four patients that were enrolled had all failed
or relapsed following induction chemotherapy, much like human patients on CAR T cell
trials (Porter et al., 2015), and CAR T cells were generated from their enriched PBLs
using the aAPC method described. Details of each of their histories, treatments, and
results are described below.
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Treatment of Patient 429-001
Patient 429-001 was diagnosed with at least stage IIIa B cell lymphoma, and treated with
CHOP chemotherapy. Patient was declared to be in complete clinical remission after two
months of therapy, but relapsed four months later. Patient was referred for CAR T cell
therapy at this time, and blood for ex vivo T cell culture and modification was drawn 30
days before infusion. In the intervening time, the patient developed a urinary tract
infection which was successfully treated with antibiotics and resolved before receiving a
pre-conditioning regime of busulfan IV on two consecutive days (-2 and -1) prior to
infusion. Histopathology of a biopsy sample taken 2 days prior to infusion from the left
submandibular lymph node (Figure 3.4) was described as follows: "the lymph node
architecture is effaced and replaced by sheets of neoplastic intermediate to large
lymphocytes (nuclei measuring 1.5-2 times the size of a red blood cell). Mitoses average
5-8 in a single high power-field (mid-grade). Scatter tingible body macrophages are
present."
Cells from Patient 429-001 expanded 153-fold over the course of 14 days, and had 6.46%
surface expression of the CAR by flow cytometry (Figure 3.5a). The majority of the
CD5+ T cells were CD8+, with a large CD4+CD8+ population (Figure 3.5b). Due to the
urinary tract infection, cells were cryopreserved. A portion of the lentivirus-infected cells
were thawed 5 days prior to scheduled infusion, and co-cultured with irradiated CLBL-1
target cells to expand the number of CAR T cells; at the time of infusion, the frequency
of T cells expressing the CAR on their surface had increased to 29% (Figure 3.5c),
demonstrating functionality and increasing the number of CAR T cells to infuse. With the
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goal of treating the patient with an estimated 105 CAR T cells per kilogram and 106 total
T cells per kilogram, additional non-infected cells that were cultured in parallel were
thawed and mixed into the infusion product. The final infusion product contained an
estimated 0.97x105 CAR T cells/kg, and 1.13x106 total T cells/kg, and was administered
IV.
Four days after infusion, the volume of the target lymph node decreased 52% (24.1 cm3
to 11.66cm3), coinciding with a 82% increase (1.88% to 3.43%) in the frequency of
CD5+ T cells within another lymph node (Figure 3.5d). The CD5+ T cell frequency in
the lymph node dropped afterward, falling below 1% 14 days post-infusion and
remaining there, as the target node then grew rapidly, reaching 92.32 cm3 26 days after
infusion. The patient developed seizures at this timepoint, and was treated with Lasparaginase as rescue therapy at day 27 post-infusion and continued on anti-epileptic
medication as well as vincristine and cyclophosphamide chemotherapy. The patient
developed seizures again 68 days post-infusion, and a brain MRI revealed a mass. The
patient’s owners elected to euthanize at this time, and the autopsy determined the mass to
be lymphoma. The number of peripheral CD5+ T cells was greatest at the time of
infusion and declined during the course of follow-up, and the number of CD79a+ B cells
rapidly increased following day 14 post-infusion (Figure 3.5e). The frequency of CD4+
and CD8+ T cells in the peripheral blood was stable throughout, and there was a decline
in both populations among CD5+ T cells in the lymph node at the final timepoint of day
26 post-infusion (Figure 3.5f). CD28 expression among the CD4+ T cells in the
peripheral blood decreased at day 26 post-infusion while remaining stable in peripheral
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CD8+ T cells, but within the lymph node CD28 expression steadily declined after 4 days
post-infusion (Figure 3.5g). Molecular evidence for the presence or expansion of CAR T
cells in vivo by qPCR for lentiviral integration within genomic DNA was not found. Of
note, the patient did develop a profound and lasting thrombocytopenia and as well as a
transient neutropenia, an expected side effect of the busulfan pre-conditioning (Figure
3.5h,i). These flow cytometry data of T and B cells are consistent with the brief
amelioration and then decline in patient health, suggesting a T cell component in
determining the disease outcome.

Treatment of Patient 429-002
Patient 429-002 was diagnosed with at least stage IIIa B cell lymphoma, and treated with
CHOP chemotherapy. The patient’s disease progressed over the next two months and the
dog was switched to a MOPP (mustargen, vincristine, procarbazine, predinosone)
chemotherapy regimen that is also used in humans, but did not respond. The patient was
referred for CAR T cell therapy, and blood for ex vivo T cell culture and modification
was drawn 16 days before infusion. In the intervening time, the patient continued
receiving MOPP chemotherapy.
Cells from Patient 429-002 grew only 22-fold over the course of 15 days, and had 1.51%
surface expression of the CAR by flow cytometry (Figure 3.6a). The plurality of the
CD5+ T cells were CD4+, with large CD4+CD8+ and CD4-CD8- populations (Figure
3.6b). Due to the small number of cells, the one million CAR T cells were injected
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directly into the most advanced tumor site, the left prescapular lymph node, to assess
local effect. The remaining non-transduced T cells that were cultured in parallel were
infused IV. The patient was treated with an estimated 0.28x105 CAR T cells/kg and
3.78x106 total T cells/kg.
14 days post-infusion, the volume of the injected left prescapular lymph node had
remained largely unchanged (an increase of 1.72%), whereas the control non-injected
right prescapular lymph node had doubled in volume (an increase of 113%) (Figure 3.6c);
the left and right submandibular lymph nodes, also not injected with CAR T cells, had
roughly doubled in volume as well (increases of 99% and 119%, respectively). In light of
the rapidly advancing disease at all sites outside of the injected lymph node, the patient
was treated with L-asparaginase chemotherapy as rescue treatment at 14 days postinfusion. Some of the tumors were refractory to treatment, and the right prescapular
lymph node had nearly tripled (196% increase) by day 28 post-infusion, and the injected
lymph node had also begun to grow at this time (52% increase) (Figure 3.6c); the owners
of the patient elected for euthanasia at day 32 post-infusion. In the first 14 days that
lymph node aspirate data were available, minor increases in CD5+ T cells and minor
decreases in CD79a+ B cells were observed in the injected left prescapular lymph node,
while the control right prescapular lymph node demonstrated the opposite trend in this
time (Figure 3.6d). Peripheral blood counts showed a consistent decline in CD5+ T cells
from before infusion through post-infusion, while CD79a+ B cell counts varied (Figure
3.6e); CBC determined no lymphocytes present at day 14 post-infusion though CD79a+
and CD5+ cells were still detected by flow cytometry. Frequencies of CD4+ and CD8+ T
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cells remained stable through 14 days post-infusion in the peripheral blood and left
prescapular lymph node, with an increase in CD8+ and decrease in CD4+ at day 14 postinfusion in the right prescapular lymph node (Figure 3.6f). CD28 expression among both
CD4+ and CD8+ T cells declined in the peripheral blood and right prescapular lymph
node, but remained stable in the left prescapular lymph node (Figure 3.6g). qPCR for the
presence of the CAR in the left prescapular lymph node was positive only at day 4 postinfusion (44.71 copies/μg genomic DNA). The contrast between the injected lymph node
and all other sites suggested a role for the small number of CAR T cells used in
mediating temporary, local control.

Treatment of Patient 429-003
Patient 429-003 was diagnosed with at least stage IIIa B cell lymphoma, and treated with
a novel indenoisoquinoline drug as part of another study. The patient then received
CHOP chemotherapy one month later, and obtained a rapid clinical remission in two
weeks. The patient relapsed six months later. Patient was referred for CAR T cell therapy
at this time, and blood for ex vivo T cell culture and modification was drawn 13 days
before infusion. In the intervening time, patient received 188mg/m2 of cyclophosphamide
over the course of four days, finishing 2 days prior to infusion.
Cells from Patient 429-003 grew 169-fold over the course of 12 days, and had 6.62%
surface expression of the CAR by flow cytometry (Figure 3.7a). The majority of CD5+ T
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cells were CD8+, with a large CD4+CD8+ population (Figure 3.7b). An estimated
6.60x105 CAR T cells/kg and 33.47x106 total T cells/kg were infused IV.
The two tracked lymph nodes, the right and left submandibular, remained relatively
stable in volume until 48 days post-infusion and disease progressed at day 64 postinfusion (Figure 3.7c). After disease progression, patient was treated with L-asparaginase
at day 64 post-infusion, and was treated with further L-asparaginase and prednisone as
necessary to maintain stable disease; after severe decline in health, the owner elected for
euthanasia at day 167 post-infusion. The composition of the right popliteal lymph node
was roughly 2:1 B cells to T cells at the time of infusion (Figure 3.7d, 66.6% to 30.9%,
respectively). This varied following infusion until it reached a period of stable T cell
dominance, beginning at day 28 post-infusion until it returned to majority B cells at the
time of disease progression at day 64 post-infusion. A population expressing lower
amounts of CD79a, matching a small lymphocyte population, became prominent at day
14 post-infusion and could be seen until its disappearance at day 64 post-infusion (Figure
3.7e). Beginning at Day 21, the expression of cCD20 on CD79a+ B cells began to
diverge into two populations, and remained at two levels until day 64 post-infusion
(Figure 3.7e); during the period when there were two levels of cCD20 expression, the
population expressing lower levels comprised 40-45% of CD79a+ B cells. Within the
peripheral blood, CD79a+ B cells and CD5+ T cells both increased in the 9 days postinfusion, following by declines in both through day 28 post-infusion; at this point, the B
and T cell populations diverge, with increases in T cells counts and stable B cell counts
through day 48 post-infusion, and then a drop in T cells and increase in B cells at day 64
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post-infusion (Figure 3.7f). T cells had increased and B cells decreased during the drugcontrolled stable disease at day 111 post-infusion. The majority of peripheral T cells were
CD4+ until day 36 post-infusion, when the frequency of CD8+ T cells became transiently
predominant, then equal at day 48 post-infusion and majority CD4+ at day 64 postinfusion; the lymph node composition of CD4+ and CD8+ T cells remained relatively
stable (Figure 3.7g). CD28 expression among both CD4+ and CD8+ T cells in both the
peripheral blood and the lymph node dramatically increased at day 28 post-infusion and
was maintained until day 64 post-infusion, tracking with the CD5+ T cell dominance in
the lymph node and expansion in the peripheral blood (Figure 3.7h). The CAR was
present in the peripheral blood through day 21 post-infusion, as measured by qPCR of
genomic DNA taken from PBMCs (Figure 3.7i). CAMA was detected in the patient
serum beginning at day 28 post-infusion, and increased through following timepoints
(Figure 3.7j).

Treatment of Patient 429-004
Patient 429-004 was diagnosed with stage IV B cell lymphoma, and treated with CHOP
chemotherapy. Patient was declared in clinical remission after one month, before
relapsing seven months later. Patient was referred for CAR T cell therapy at this time,
and blood for ex vivo T cell culture and modification was drawn 14 days before infusion.
In the intervening time, patient received L-asparaginase and 197.5mg/m2 of
cyclophosphamide over the course of four days, finishing 2 days prior to infusion.
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Cells from Patient 429-004 grew 73-fold over the course of 13 days, and had 3.68%
surface expression of CAR by flow cytometry (Figure 3.8a). The frequency of CD5+
CAR T cells was abnormally low at the end of culture, 47.4% compared to greater than
90% for the other three patients (Figure 3.8b). The CD5- cells were negative for CD79a
or hCD45 (Figure 3.8c). The plurality of CD5+ T cells were CD4+, with large
CD4+CD8+ and CD4-CD8- populations (Figure 3.8d). An estimated 5.01x105 CAR T
cells/kg and 33.61x106 total T cells/kg were infused IV, similar to Patient 429-003.
Four days post-infusion, all six of the tracked lymph nodes - the left and right
submandibulars, prescapulars, and popliteals - had all increased in size, with the increase
in the longest dimension of the node ranging from 15% to 115% (Figure 3.8e). The
frequency of CD79a+ B cells in the right popliteal node had also increased with a
corresponding decrease in CD5+ T cells (Figure 3.8f). Peripheral blood counts of
CD79a+ B cells and CD5+ T cells was tracked for 45 days post-infusion (Figure 3.8g).
qPCR for the presence of the CAR detected a signal in the right popliteal lymph node 45
days post-infusion (18.28 copies/μg genomic DNA), but only in 2 of 3 replicates.
Patient was treated with L-asparaginase as rescue chemotherapy day 5 post-infusion, and
disease was stabilized with vincristine, cytosine-arabinoside, and lomustine, until
progression at day 45 post-infusion. Owners elected to euthanize day 59 post-infusion.
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Patient survival correlates with ex vivo T cell expansion
To investigate factors that may be related to therapy efficacy, overall survival of all four
patients post-infusion was examined. Unexpectedly, survival did not correlate with the
dosage of total T cells or even CAR T cells, but rather how well the cell expanded ex vivo
during culture (Figure 3.9, p = 0.0417). This is best illustrated in the contrast in outcomes
for Patients 429-003 and 429-004, despite similar total T cell and CAR T cell dosing. As
cells from all patients were cultured the same way, this would suggest something intrinsic
to the patient that affected the starting population of T cells that were isolated for product
generation.
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Figure 3.1. Comparison of CMV and EF-1α promoters in lentivirally transduced canine T
cells. PBMCs from four healthy dogs were stimulated with Beads and infected with equal
amount of pCLPS GFP (CMV promoter) or pELNS GFP (EF-1α promoter) lentivirus in
parallel. Day 6 post-stimulation, live lymphocytes were analyzed by flow cytometry for
(a,b) frequency and (a,c) MFI of GFP+ cells. Gated on live CD5+ cells, GFP+
determined by non-transduced cells from the same donor. Lines in b and c connect results
from the same donor under different conditions.
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Figure 3.2. Activation of canine T cells and elimination of aAPCs during culture.
Enriched PBLs from three healthy dogs were stimulated with aAPCs, agonistic anticanine CD3, and rhIL-2 and rhIL-21. (a) Frequency of CD25low and CD25high
expressers among live CD5+ cells measured by flow cytometry. Data representative of
one of two independent experiments with three healthy dogs each. (b) aAPCs were
enumerated by measuring live hCD45+ cells and normalizing to CountBright beads and
comparing to the initial number added to culture. Data representative of one of two
independent experiments with three healthy dogs each. Means ± SEM represented in both
a and b.
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Figure 3.3. Design and function of cCD20-8-28-ζ canine CAR T cells ex vivo. (a)
Diagram of cCD20-8-28-ζ construct. (b) Amino acid sequence of CAR construct, colorcoded by domain as in a. (c) CAR surface expression among live CD5+ cells measured
by flow cytometry 14 days after stimulation with aAPCs and infection with pELxPS (EF1α promoter) cCD20-8-28-ζ lentivirus. (d) Lysis of irradiated GL-1 (cCD20-) cells and
CLBL-1 (cCD20+) cells after overnight co-culture with 1 T cell per 1 Target or 5 T cells
per 1 Target, as calculated from enumerating live CD79a+ target cells by flow cytometry
and normalizing to CountBright beads. Means ± SEM of triplicate wells represented. (e)
CAR surface expression among live CD5+ cells measured by flow cytometry before and
after 1 and 2 co-cultures with irradiated CLBL-1 cells at a 1:1 T cell:CLBL-1 ratio. (f)
Absolute number CAR T cells calculated from total cell counts measured by trypan blue
exclusion and the frequency of CD5+CAR+ cells among live cells measured by flow
cytometry.
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Figure 3.4. Histopathology of biopsy from Patient 429-001's left submandibular lymph
node. Hematoxylin and eosin stain of a Tru-cut biopsy taken from Patient 429-001's left
submandibular lymph node 2 days prior to CAR T cell infusion, 40x magnification.
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Figure 3.5. Treatment of Patient 429-001. (a) Surface expression of the CAR on live
CD5+ cells as measured by flow cytometry at the end of initial culture. (b) CD4 and CD8
expression on live CD5+ T cells as measured by flow cytometry at the end of initial
culture. (c) Surface expression of the CAR on live CD5+ cells as measured by flow
cytometry at the end of co-culture with irradiated CLBL-1 target cells and before
infusion. (d) The calculated ellipsoid volume of the left submandibular lymph node (left
axis, blue line) and the frequency of CD5+ cells (right axis, red line) among live cells
within the right submandibular lymph node as measured by flow cytometry over time
relative to CAR T cell infusion. (e) Absolute numbers of CD79a+ (blue line) and CD5+
(red line) cells over time relative to CAR T cell infusion, calculated from flow cytometry
and CBC. (f,g) Frequency in the peripheral blood and lymph node of (f) CD4+ and CD8+
cells among live CD5+ cells and (g) CD28+ cells among live CD4+ or CD8+ cells
measured by flow cytometry over time relative to infusion.
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Figure 3.6. Treatment of Patient 429-002. (a) Surface expression of the CAR on live
CD5+ cells as measured by flow cytometry at the end of initial culture. (b) CD4 and CD8
expression on live CD5+ T cells as measured by flow cytometry at the end of initial
culture. (c) Percent change in calculated ellipsoid volume of the left (blue line) and right
(red line) prescapular lymph nodes over time relative to CAR T cell treatment. (d)
Frequency of CD79a+ (blue line, left axis) and CD5+ (red line, right axis) cells among
live cells in the left and right prescapular lymph node as measured by flow cytometry
over time relative to CAR T cell treatment. (e) Absolute numbers of CD79a+ (blue line)
and CD5+ (red line) cells over time relative to CAR T cell treatment, calculated from
flow cytometry and CBC. (f,g) Frequency in the peripheral blood and lymph node of (f)
CD4+ and CD8+ cells among live CD5+ cells and (g) CD28+ cells among live CD4+ or
CD8+ cells measured by flow cytometry over time relative to CAR T cell treatment.
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Figure 3.7. Treatment of Patient 429-003. (a) Surface expression of the CAR on live
CD5+ cells as measured by flow cytometry at the end of initial culture. (b) CD4 and CD8
expression on live CD5+ T cells as measured by flow cytometry at the end of initial
culture. (c) Calculated ellipsoid volume of the left and right sumandibular lymph nodes
over time relative to infusion. (d) Frequency of CD79a+ (blue line, left axis) and CD5+
(red line, right axis) cells among live cells in the right popliteal lymph node as measured
by flow cytometry over time relative to infusion. (e) CD79a and cCD20 expression
among live cells within the right popliteal lymph node as measured by flow cytometry
over time relative to infusion. (f) Absolute numbers of CD79a+ (blue line) and CD5+
(red line) cells over time relative to infusion, calculated from flow cytometry and CBC.
(g,h) Frequency in the peripheral blood and lymph node of (g) CD4+ and CD8+ cells
among live CD5+ cells and (h) CD28+ cells among live CD4+ or CD8+ cells measured
by flow cytometry over time relative to infusion. (i) Copies of integrated CAR gene per
μg of PBMC genomic DNA over time relative to infusion, as measured by qPCR. (j)
Levels of serum CAMA over time relative to infusion, as measured by ELISA with
means ± SEM of well triplicates represented and the assay LLOD marked by the dashed
line.
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Figure 3.8. Treatment of Patient 429-004. (a) Surface expression of the CAR on live
CD5+ cells as measured by flow cytometry at the end of initial culture. (b) Frequency of
CD5+ cells among live cells as measured by flow cytometry at the end of initial culture.
(c) Expression of CD79a and hCD45 among live CD5- cells as measured by flow
cytometry at the end of initial culture. (d) CD4 and CD8 expression on live CD5+ T cells
as measured by flow cytometry at the end of initial culture. (e) Length of the longest
dimension of three pairs of contralateral lymph nodes as measured by calipers over time
relative to infusion. (f) Frequency of CD79a+ and CD5+ cells among live cells in the
right popliteal lymph node at baseline (left) and day 4 post-infusion (right) as measured
by flow cytometry. (g) Absolute numbers of CD79a+ (blue line) and CD5+ (red line)
cells over time relative to CAR T cell treatment, calculated from flow cytometry and
CBC.
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Figure 3.9. Correlations between infusion product and patient overall survival. Days of
patient overall survival following CAR T cell therapy plotted against total T cells/kg
infused, CAR T cells/kg infused, or the rate of cell product growth. Linear regression
with R2 value, Spearman’s rho value, and p value shown.
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Discussion
Using lentivirus, we were able to permanently transduce primary canine T cells to
express a second-generation cCD20-8-28-ζ CAR. Those canine CAR T cells were able to
kill target antigen-expressing cells and proliferate in response to them in vitro, resulting
in more CAR T cells. Antigen-induced CAR T cell expansion continued upon antigen rechallenge, a positive indicator for anti-tumor response amplification in vivo. However,
the decline in CAR T cells following the third challenge is concerning, given the shorter
half-life of CD28-based CAR T cells in human clinical trials; this shorter half-life in
human patients is believed to be due to exhaustion (Long et al., 2015). It should be noted
that this preliminary result was from only one dog, and testing in further donor T cells
with this CAR construct is needed for conclusive interpretation.
Based on these data, we treated four canine patients with relapsed or refractory B cell
lymphoma with autologous cCD20-8-28-ζ CAR T cells. At their current stage of disease,
the expected median response would be expected to only last in the range of 1-2 months,
even if they had received aggressive rescue chemotherapy (Vail et al., 2013). None of the
patients reached an objective response, but observations from each of them informed the
treatment of the next.
The inverse relationship between T cell frequency in the lymph node and tumor
outgrowth in Patient 429-001 suggested that the CAR T cells could traffic to the tumor
site and exert an anti-tumor effect. However, the loss of T cells within the lymph node
followed by outgrowth of that tumor, suggest that the lack of T cell persistence may have
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contributed to therapy failure – just as CD28-based CAR T cells often fail to persist in
human patients. While neurotoxicity has been observed in human patients, it is more
likely that Patient 429-001’s seizures and abnormal behavior were due to the brain
metastasis It should be noted that brain metastasis of B cell lymphoma is unusual, and
leads one to speculate whether the CAR T cell infusion exerted pressure on malignant
cells to move to an immunoprivileged niche (Seo et al., 2011).
The product generated from Patient 429-002’s cells was suboptimal, likely due to
ongoing treatment with a MOPP chemotherapy regimen when the cells were isolated for
culture, and unlikely to halt or reverse clinical progression of disease. Nevertheless, we
injected one tumor with the CAR T cells and let the others receive non-transduced T cells
from circulation and found that the CAR T cells could exert local tumor control.
Based on this evidence, our next goal was to increase overall CAR T cell numbers
throughout the patient, which occurred with Patient 429-003. In this case, the patient’s
disease became stable for two months, and survived for five months after infusion.
Patient 429-003 provided a wealth of observations to consider. While the most striking
data is that the dog survived 169 days post-infusion, 1-2 month survival after relapse is
only an average and this patient may have been a naturally-occurring outlier even if it had
not been treated with CAR T cells. However, the convergence of several observations
forms a hypothetical timeline for transient effects and efficacy of the treatment. During
the first three weeks after infusion with CAR T cells, qPCR can detect presence of the
CAR in the peripheral blood and the dominance of the B and T cells in the lymph node
goes back and forth until a T cell majority is achieved, and the B cell population begins to
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modulate its expression of cCD20 – the target antigen of the CAR. Four weeks after
infusion with the CAR T cells, an anti-CAR immune response is formed in the form of
CAMA and CAR T cells can no longer be detected in the peripheral blood by qPCR. In
the weeks that follow, the CAMA increases, the T cells can no longer control the
malignant cells in the lymph nodes which grow, and cCD20 expression the B cells
returns to normal.
Whether the CAR T cells disappeared because they were eliminated by the CAMA or
because they became exhausted and declined on their own, for which the ex vivo rechallenge data may have been a harbinger, is unclear, but the suggestion is that presence
of the CAR T cells played a role in exerting some control of the lymphoma and their loss
led to its progression. It is unclear why Patient 429-003 continued to survive over 100
days past progression if the CAR T cells were gone; perhaps the non-transduced ex vivo
cultured T cells continued to have a positive effect, as suggested in another canine trial
using adoptively transferred T cells (O'Connor et al., 2012). Perhaps the early CAR T
cell-mediated control of the tumor allowed time for the recovery of the host’s other T
cells, as suggested by the increase in CD28 expression, which were able to keep the
disease at bay for an extended period of time with assistance of the L-asparaginase and
prednisone. It is also unknown whether the change in cCD20 expression was even a
decrease since each sample was stained and run at the time of collection, but qPCR and
sequencing of cryopreserved samples could potentially elucidate this or possible escape
mutants.
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That Patient 429-003 alone generated CAMA is particularly fascinating. The one other
patient that demonstrated this, 434-001 in Chapter 2, had been injected 3 times with
transiently-expressing CAR T cells, which could explain a vaccination-like effect against
the CAR. Patient 429-003 was infused only once, but, unlike the other three patients that
received the permanently-expressed cCD20-8-28-ζ CAR, it had evidence of extended
presence of CAR T cells in vivo – a persistently present antigen to form CAMA against.
Additionally, Patient 429-003 never eliminated its B cell compartment, just a two monthlong stalemate during which the surviving B cells had ample opportunity to form a
response against the CAR. HAMA is typically not measured in human patients receiving
B-cell targeting CAR T cells, but our canine data highlights a potential risk to human
patients if additional infusions of CAR T cell are attempted when an objective response is
not achieved. In fact, in the one publication of human B cell lymphoma patients treated
with CAR T cells that did examine anti-CAR immune responses, CD8+ T cell activity
against peptides generated from the scFv component of the CAR was detected in patients
that did not receive the more potent pre-conditioning chemotherapy regimen and left the
patients’ immune compartments more intact (Turtle et al., 2016).
Our attempt to replicate our findings with Patient 429-003 in Patient 429-004 failed, with
rapid progression only 4 days after infusion despite similar numbers of total and CAR T
cells. This experience taught us two important lessons. First, that the number of cells do
not matter so much as their quality, as measured in proxy by their ability to expand ex
vivo before infusion. The second was a reminder of the rapidity of this disease in dogs,
which may not allow for culturing the cells for two weeks or longer and only give a
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narrow window of opportunity for the treatment to work in vivo; in fact, the dog
represented in Figure 3.3e-f, whose cells killed lymphoma cells and expanded ex vivo,
was a B cell lymphoma patient being screened for this trial but died before it could be
treated.
These observations regarding T cells dosage are interesting in light of data from CAR T
cell trials in human B cell lymphoma patients. Dosages in the range of 105 CAR T
cells/kg, 106/kg, and 107/kg showed that increasing from 106 to 107 did not increase
clinical efficacy, just severity of neurotoxicity and CRS (Turtle et al., 2016). The primary
determining factor for both efficacy and toxicity in these patients was more potent preconditioning chemotherapy in the form of combined cyclophosphamide and fludarabine.
Our dosages were in the range of 105 to 106 CAR T cells/kg and we did not use
fludarabine, which may explain the limited efficacy. This may also explain why we did
not see any clinical signs of CRS, though CBA data from patient serum samples are
pending.
In Patients 429-001 and 429-003, which remained on the trial long enough to better
assess trends, it is particularly interesting that the expression of CD28 on the T cells
corresponds with the "success" of the T cells at that timepoint. In 429-001, at day 4 postinfusion when the target node shrinks and the peripheral and lymph node T cells increase,
the frequency of CD28+ T cells is increased. As disease progresses, the frequency of
CD28+ T cells decrease. In Patient 429-001, given the brief spike shortly after infusion, a
possible explanation is that the infusion product contained a large number of CD28+ T
cells, and that these cells eventually died or lost expression of the co-stimulatory receptor
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as they terminally differentiated or were otherwise suppressed by the tumor. In Patient
429-003, the parallel between the T cells becoming predominant in both the peripheral
blood and the lymph node and the jump in CD28 expression at both sites during the time
period between days 28 and 48 post-infusion and the rapid decline of both at day 64 postinfusion is remarkable. That this occurred 4 weeks after infusion suggests that it is not
just a transient boost from cells that have just been infused, but perhaps CD28 expression
can be used as a broader marker of T cell health within the patient. This hypothesis is
explored further in Chapter 4.
The takeaway from this trial can be summarized in Figure 3.9, that quality of the T cells
matters more than quantity for therapy efficacy. This quality could take a variety of
forms. It could be the chemotherapy that the T cells were exposed to while in the patient
prior to isolation; all patients did receive CHOP chemotherapy months prior to isolation,
but Patient 429-002, whose T cells only grew 22-fold, was receiving a chemotherapy
regimen (MOPP) at the time of isolation. While all the patients had progressive disease at
the time of relapse, they were not staged until the time of infusion; each patient’s disease
may have had different levels of immunosuppressive effects on their T cells that were
then isolated. Indeed, since our starting product for culture was enriched PBLs, residual
malignant cells or suppressive myeloid populations may have continued to have
detrimental effects on the T cells ex vivo; the extent of this potential contamination’s
effect could very well vary from patient to patient. We were unable to phenotype the
patients’ T cells for surface inhibitory receptors due to a lack of reagents. Similarly, a
starting population of T cells that is predominantly central memory cells or terminally
92

differentiated effector cells would have very different expansion results, but our reagents
for differentiating those phenotypes were limited at the time. Our observations of T cell
expansion could be indicative not just of the health of individual T cells, but also of a
variety of factors that affect the entire T cell compartment of the patient, and the T cell
compartment of the patient itself may be a proxy for the aggressiveness of the disease. By
extension, the ability of a patient’s T cells to expand ex vivo may be prognostic of their
future disease course and overall survival, independent of whether they are treated with
those ex vivo expanded T cells.
CAR T cell therapy depends not only on the CAR, but the T cell that bears it as well.
Chapters 2 and 3 have demonstrated that it is possible to redirect primary canine T cells
with a CAR to target spontaneously-occurring tumors in vivo for therapy, even
establishing stable disease. In order to make the next step toward successful therapy, we
will need to examine the quality of the T cells we isolate from patients to generate their
products, how we can improve our culture system to retain or generate desirable subsets
of T cells that will have greater therapeutic effect, and alter our CAR construct so that it
not only targets the tumor but also reinforces these preferred T cell qualities. In short,
Chapter 4 focuses on building a better T cell.
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CHAPTER 4: Improvements in Canine CAR T Cell Generation & Their Effect on a
Canine B Cell Lymphoma Patient

Abstract
Successful CAR T cell therapy hinges upon both an effective tumor-targeting CAR
construct and T cells capable of long-lived and robust function to bear it. In Chapters 2
and 3, we successfully developed a cCD20-targeting CAR and achieved permanent
expression of it in primary canine T cells. In this chapter, we identified factors that are
deleterious to T cells taken from patients and ways to potentially recover these cells. We
also altered our culture system to combine stimuli and promote canine memory-like T
cells through use of rhIL-7 and rhIL-15, and generated a cCD20-8-BB-ζ CAR that
appears more resistant in CAR-induced exhaustion. The sum of these findings were
applied in the treatment of a canine patient with stage V B cell lymphoma, who had
molecular evidence of CAR T cell persistence for at least 50 days post-infusion. In
addition, the patient’s tumor lost expression of the CAR antigen, suggesting adaptation in
response to cCD20-targeting therapy-mediated immune pressure just as observed in
human CAR T cell patients.
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Introduction
Data from Chapters 2 and 3 have demonstrated that canine T cells can be redirected
against antigen-bearing tumor targets using a CAR, and that this CAR can be
permanently expressed in canine T cells and infused back into patients for temporary or
local tumor control. In the course of these experiments and clinical observations, the data
repeatedly pointed us in the direction of the role that T cell quality may play in efficacy.
Therefore, we explored the quality of the cells we obtained from dogs, how we could
adapt our culture system to improve the quality, compared CAR constructs to see if
activity through them altered the quality of the cells, and other factors that we thought
may affect therapy efficacy.
Our first comparison of stimuli in Chapter 2 (Figure 2.1) raised two questions: why do
aAPCs outperform Beads in growing T cells, and why do some dogs respond to Beads
while others do not? As the Beads can only give stimulation through CD3 and CD28, we
hypothesized that different levels of CD28 expression on donor or patient T cells was the
cause for different proliferative responses. Our attention was drawn to CD28 expression
once more in Chapter 3, when we observed that frequency of CD28+ T cells in vivo
tracked with tumor control in our CAR T cell-treated patients. For this reason, we
undertook preliminary investigations into CD28 expression in donor T cells and its effect
on proliferation in response to different stimuli. In the same vein of exploring potential
determining factors in T cell health and growth, we examined the effects of recent
chemotherapy on the expansion of T cells isolated from patients. Both of these factors,
patient-to-patient variation in T cell phenotype and prior therapies, are of significant
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consequence to human CAR T cell therapy but are entirely absent in immunodeficient
mouse-xenograft studies.
We also revisited two key aspects of our culturing system. First is the form and timing of
stimulus; transduction of human T cells with lentivirus is typically performed within the
initial 48 hours, whereas we have delayed until 4 days post-stimulation because the
presence of aAPCs in culture. An increase in transduction efficiency would increase the
number of CAR T cells infused into the patients; while CAR T cell dose did not correlate
with overall survival in the clinical trial with cCD20-8-28-ζ CAR T cells (Figure 3.8),
starting with a larger number of CAR T cells may blunt possible rapid tumor progression
in the days immediately following infusion as occurred with Patient 429-004. The second
component of our culture system we reassessed was cytokine supplementation. rhIL-2
and rhIL-21 use in culturing canine T cells was reported previously, and we used this in
Chapters 2 and 3 since we found that it generated large numbers of T cells with increased
expression of granzyme B (O'Connor et al., 2012). However, this could potentially mean
that these cells were closer to terminal differentiation as effector cells which would not
persist in vivo. Stem- or naïve-like memory cells that are longer-lived and more
pluripotent in their T cell fates have been identified in humans, and their increased
presence in CAR T cell products infused into human patients is associated with increased
in vivo expansion – the strongest correlate of therapy success (Gattinoni et al., 2011; Xu
et al., 2014). Studies with human cells have found that ex vivo culture with IL-7 and IL15 preserves this T cell phenotype better than culture with IL-2, as does shorter culture
times (Ghassemi et al., 2016; Xu et al., 2014).
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The clinical trial reported in Chapter 3 used a second-generation CAR construct
containing the intracellular signaling domain of CD28. The other most commonly used
construct uses the intracellular signaling domain of the co-stimulatory receptor 4-1BB
(BB). BB-based CAR T cells were found to have longer persistence in mouse studies, and
recent publications have demonstrated that human T cells that receive a signal through a
BB-containing CAR skew toward a central or stem-like memory fate rather than effector
or effector memory fate as seen with as CD28-containing CARs, in part through the
metabolic and gene expression shifts that accompany either CAR’s signaling (Carpenito
et al., 2009; Kawalekar et al., 2016; Long et al., 2015; Milone et al., 2009). This
difference is particularly important in CARs that have scFvs that have a tendency to selfligate, resulting in continuous tonic signaling that can cause the cells to spiral toward
exhaustion depending on the co-stimulatory domain used (Frigault et al., 2015; Long et
al., 2015). The eventual decline of CAR T cells we observed during ex vivo challenge
(Figure 3.3f) and evidence of only brief presence within patients when using the cCD208-28-ζ CAR construct led us to develop and test a cCD20-8-BB-ζ CAR in primary canine
T cells.
The findings of all these experiments led us to an improved protocol for generating
canine CAR T cells that use the BB domain, which we used to treat a canine patient with
spontaneous B cell lymphoma. This patient is still being monitored, and the results to
date are described here.
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Results
Canine patients with late-stage lymphoma have low frequency of CD28-expressing
CD4+ T cells and are unresponsive to Bead stimulation
We compared the CD28 expression on T cells isolated from two dogs with late-stage
lymphoma to six healthy controls dogs. While the frequency of CD28+ cells among
CD8+ T cells was comparable (43.40 ± 1.50% vs. 39.77 ± 4.70%, respectively), it was
dramatically decreased among the CD4+ T cells of the diseased dogs (17.10 ± 1.50% vs.
90.68 ± 4.83%, respectively; Figure 4.1a). PBMCs from the two diseased dogs and a
healthy control were stimulated with either Beads or aAPCs for 8 days, without cytokines
to exclude other growth factors. While the healthy PBMCs grew equivalently with either
stimuli (22.3-fold for Beads, 18.9-fold for aAPCs), PBMCs from the diseased dogs only
grew in response to the aAPCs (9.0-fold and 6.2-fold for the two dogs with aAPCs).
While the proliferative response of the diseased dog PBMCs to aAPCs was diminished in
comparison to healthy dog PBMCs, indicative of other obstacles to proliferation, this is in
stark contrast to the stimulation with Beads, with had few live cells remaining at the end
of culture (Figure 4.1b). Frequency of CD28+ CD4+ and CD8+ T cells increased among
the diseased dogs’ PBMCs during the culture with aAPCs, and the T cells were
responsive to Bead stimulation after this (Figure 4.1c, data not shown). These data
suggest that T cells from canine patients with advanced disease may not respond to Bead
stimulation due to decreased expression of CD28 on their CD4+ T cells, and that aAPCs
may recover these cells.
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aAPCs grow more Canine T cells than Beads through cell-intrinsic, contact-dependent
and -independent factors
To identify the mechanism of how aAPCs support the growth of canine T cells better
than Beads, we attempted to separate out the components of the stimulus. Beads and
aAPCs both use the same agonistic anti-canine CD3 antibody, but Beads use an agonistic
anti-canine CD28 antibody while aAPCs express canine CD86 – the ligand for CD28 – to
provide co-stimulation. To determine if the source of co-stimulation via CD28 was the
cause, we used an intermediate aAPC system: the same baseline K562 expressing human
CD32 but without canine CD86, with the same agonistic anti-canine CD3 and CD28
antibodies as on the Beads. PBMCs from three healthy dogs were stimulated with Beads,
aAPCs, or the intermediate aAPCs that used only the agonistic antibodies. The
intermediate aAPC system grew canine T cells just as well as the aAPC system (15.83 ±
3.68-fold vs. 14.38 ± 1.15-fold, respectively), and both of them better than the Beads
(8.90 ± 1.74-fold; Figure 4.2a), indicating that the source of CD28 stimulation does not
account for the growth difference, but rather a factor intrinsic to the aAPCs.
To determine if this factor was contact-dependent or not, a transwell experiment was set
up. CFSE-labeled PBMCs from three healthy dogs were stimulated with Beads at the
bottom of the transwell alone, or with aAPCs lacking canine CD86 and no soluble anticanine CD3 (Kt32 cells) either in the upper chamber separated from the PBMCs or in the
lower chamber with the PBMCs. After 4 days, the presence of Kt32 aAPCs in the upper
chamber enhanced cell division beyond that of Beads alone, and their presence in the
lower chamber with the PBMCs enhanced it even further (Figure 4.2b). This would
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suggest that the Kt32 aAPCs provide both soluble and cell-contact factors outside of CD3
and CD28 binding to further stimulate growth of canine T cells. As human CD8+ T cells
that lack CD28 have been found to be primarily dependent on CD58-binding for costimulation, we investigated our aAPCs and found them to be positive for human CD58
(Figure 4.2c) (Leitner et al., 2015). Additionally, whereas rhIL-21 alone can upregulate
granzyme B expression in canine T cells cultured with aAPCs (Figure 2.2b), culture with
Beads requires both rhIL-2 and rhIL-21 (Figure 4.2d), suggesting that the aAPCs are
compensating for the IL-2 requirement, perhaps through the secretion of another
cytokine.

Recent chemotherapy hinders growth of canine T cells isolated from patients
Both human CAR T cell therapy patients and canine patients that we have screened for
our trials have typically received extensive prior therapy, often profoundly cytotoxic
chemotherapy agents. In Chapter 3, we observed that cells from Patient 429-002 grew the
poorest of the four trial patients, and the blood was drawn while the patient was receiving
MOPP chemotherapy. We examined the growth of T cells from two canine lymphoma
patients that had sequential blood draws after chemotherapy to generate CAR T cell
products. Patient 434-001, described in Chapter 2, had received L-asparaginase before we
drew our first blood sample; cells taken 10 days after L-asparaginase grew 34-fold,
whereas those taken 17 and 23 days after grew 162-fold and 120-fold, respectively.
Another patient that was screened but not treated had received doxorubicin 12 days
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before the first draw; these cells expanded only 1.5-fold, but cells from blood drawn at 40
days after doxorubicin grew 27-fold. In the case of Patient 434-001, the T cells grew
better with increased time from chemotherapy in spite of advancing disease, while the
second patient was in clinical remission at both timepoints. Together, these suggest that
the ability of canine T cells to expand ex vivo is negatively impacted by recent treatment
with chemotherapy.

Beads stimulate a select population of canine T cells more robustly than aAPCs
In light of changes to our growth protocol and observations regarding differences
between aAPCs and Beads, we revisited the comparison of stimuli that was initially
performed in Chapter 2 (Figure 2.1). CFSE-labeled enriched PBLs from 4 healthy dogs
were stimulated with aAPCs, Beads, ConA, or left unstimulated, all supplemented with
rhIL-2 and rhIL-21. As before, stimulation with aAPCs outperformed that of all other
conditions, including the Beads (Figure 4.3a). Interestingly, CD5+ T cell responder
frequency two days post-stimulation was highest amongst the Beads (72.0 ± 4.0% for
Beads, 46.8 ± 2.1% for aAPCs, 20.2 ± 1.4% for ConA, and none for unstimulated; Figure
4.3b). In fact, MFI of CD25 is increased during days 1 and 2 post-stimulation in Bead
cultures compared to aAPC cultures, even when comparing cells that have undergone the
same number of mitoses or have not divided at all (Figure 4.3c). This indicates that Beads
provide a more potent activation signal to canine T cells that respond to them early in
comparison to aAPCs.
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Earlier infection of Bead-responsive cells leads to increased transduction compared to
aAPCs
As Beads are able to robustly activate a population of canine T cells, we explored
whether these cells may be more efficiently transduced with lentivirus. In addition,
Beads, unlike aAPCs, do not act as a viral sink, allowing infection with lentivirus at an
earlier timepoint than with aAPCs, which remain in culture for multiple days (Figure
3.2b). Enriched PBLs from three healthy dogs were cultured with aAPCs, or were
incubated with Beads and Bead-bound cells were then isolated and cultured. Those
cultured with aAPCs were infected on Day 4 post-stimulation, while those cultured with
the Beads were infected either Day 1 or Day 2 post-stimulation; equal MOI of GFPencoding lentivirus was used for all conditions. After 7 days of culture, T cells cultured
with the Beads were transduced at a remarkably higher efficiency than with aAPCs (24.1
± 1.5% GFP+ for Day 1 Post-Beads, 25.4 ± 2.4% for Day 2 Post-Beads, 9.8 ± 1.1% Day
4 Post-aAPCs; Figure 4.4a,b), and the transduced cells expressed higher levels of GFP
(8257 ± 1466 for Day 1 Post-Beads GFP MFI, 7072 ± 932 for Day 2 Post-Beads, 4021 ±
403 Day 4 Post-aAPCs; Figure 4.4a,c). The increased transduction during culture with
the Beads compared to the aAPCs could be due to the stimulus or the timing, but former
constrains options for the latter. These data suggest that Beads give an early, potent
activation signal to canine T cells that permits more efficient transduction, but aAPCs
stimulate more T cell growth overall, giving rise to the potential of stimulating with
Beads, infecting with lentivirus, and then supplementing the culture with aAPCs.
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Supplementation with rhIL-7 and rhIL-15 retains CD62L and CD27 expression on T cells
compared to rhIL-2 and rh-IL21
As IL-7 and IL-15 have been suggested to promote memory cell formation during ex vivo
culture of human T cells in comparison to IL-2, we compared the effects of rhIL-7 and
rhIL-15 to rhIL-2 and rhIL-21 on canine T cell culture (Xu et al., 2014). Enriched PBLs
from four healthy dogs were stimulated with Beads with rhIL-2 and rhIL-21, rhIL-7 and
rhIL-15, or no cytokines; aAPCs were not used since the additional growth factors they
provide may act synergistically with one set of set cytokines but not the other. T cell
growth rate for both sets of cytokines were similar through the first 7 days, but had
diverged in favor of rhIL-2 and rhIL-21 by day 14 of culture though with a high degree of
variability (45.1 ± 15.7-fold for rhIL-2 and rhIL-21 versus 18.1 ± 6.2-fold for rhIL-7 and
rhIL-15 at day 14 of culture; Figure 4.5a). All conditions resulted in a skewing from
mostly CD4+ to majority CD8+ among T cells (Figure 4.5b,c). CD62L and CD27
expression in both CD4+ and CD8+ T cells was higher in cells cultured with rhIL-7 and
rhIL-15 compared to rhIL-2 and rhIL-21, especially at day 14 of culture (Figure 4.5d-g).
Based on these data, culture with rhIL-7 and rhIL-15 results in early growth similar to
rhIL-2 and rhIL-21, but better retains memory-like cells that express CD62L and the costimulatory receptor CD27.
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Supplementation with rhIL-7 and IL-15 alters gene expression
qRT-PCR was performed on T cells harvested at days 7 and 14 of culture in all three
conditions to assess differences in expression profiles. Compared to T cells cultured with
rhIL-2 and rhIL-21, T cells cultured with rhIL-7 and rhIL-15 had increased expression of
CD44 and CD62L. Expression of BCL6, GZMB, and PRDM1 were relatively decreased.
Expression of EOMES and TBX21 were increased at day 7 of culture, but returned closer
to equivalent expression at day 14. (Figure 4.6)

cCD20-8-BB-ζ CAR T cells have extended ex vivo proliferative capacity in response to
antigen challenge
A CAR construct targeting canine CD20 using the same scFv as in Chapters 2 and 3 was
designed, using the following components from N to C terminus: canine CD8α leader,
murine anti-canine CD20 scFv, canine CD8α hinge, canine CD8α transmembrane, canine
4-1BB intracellular domain, and canine CD3ζ intracellular domain (Figure 4.7a, b). A
nucleotide sequence that was codon-optimized for dogs was synthesized (Figure 4.7c),
and inserted into the same lentivector (pELxPS) as used in the cCD20-8-28-ζ studies.
Surface expression of the cCD20-8-BB-ζ CAR construct was successful after
transduction of primary canine T cells (Figure 4.7d). Frequency of T cells with surface
expression of the CAR increased after sequential challenges with the cCD20-expressing
CLBL-1 canine B cell lymphoma cell line (Figure 4.7d). Absolute number of CAR T
cells increased in multiple canine donors after 3 challenges with CLBL-1 cells (Figure
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4.7e). Two of these donors were healthy dogs, and their T cells were initially cultured
with rhIL-2 and rhIL-21; cells from the third dog were grown in rhIL-7 and rhIL-15, and
continued to grow after 4 challenges, despite coming from a donor that was in remission
from B cell lymphoma. cCD20-8-BB-ζ CAR T cells from all three dogs outperformed the
cCD20-8-28-ζ CAR T cells described in Chapter 3 (Figure 3.3f, growth curve overlaid in
Figure 4.7e). cCD20-8-BB-ζ CAR T cells from the dog in remission are also capable of
lysing targets in an antigen-specific manner, killing GL-1 cells expressing cCD20 more
efficiently than those without cCD20 in an overnight luciferase assay (Figure 4.7f).

Treatment of Patient 429-006
Having developed a culture system that would potentially increase the frequency of CAR
T cells and preferentially grow memory-like cells, and developed a cCD20-8-BB-ζ CAR
construct that appears to extend proliferative capacity, we recruited a patient with limited
chemotherapy exposure to assess the efficacy of our updated CAR T cell therapy protocol
that is closer to the best practices currently used in human CAR T cell therapy.
Patient 429-006 was diagnosed with stage V B cell lymphoma with significant numbers
of circulating blasts. Initial pathology report described the malignant cells as "large
immature unclassed cells" with "finely granular chromatin, and variably distinct
nucleoli." The patient was treated with L-asparaginase and prednisone, but owners
declined continuing to CHOP chemotherapy and the patient was referred for CAR T cell
therapy; blood for ex vivo T cell culture and modification was drawn 16 days before
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infusion. In the intervening time, the patient received 10,000IU L-asparaginase,
0.56mg/m2 vincristine 9 days prior to infusion, and 283mg/m2 of cyclophosphamide over
the course of four days, finishing 3 days prior to infusion.
As the patient was leukemic at the time of blood draw and had low frequency of CD5+ T
cells, we sorted for CD5+ cells by flow cytometry, and started with an initial population
of 85.8% CD5+ T cells for culture (Figure 4.8a,b). These cells were stimulated with
Beads, infected on both day 1 and day 2 post-stimulation with lentivirus encoding the
cCD20-8-BB-ζ CAR, and were supplemented with aAPCs and agonistic anti-canine CD3
antibody on day 4 post-stimulation, receiving rhIL-7 and rhIL-15 throughout the culture
period. By day 9 post-stimulation, cells had expanded 25-fold. Half the cells were
cryopreserved while undergoing quality control testing, while the other half were restimulated using irradiated autologous PBMCs, which contained 94.8% cCD20+
leukemic blasts (Figure 4.8c). Seven days later, cryopreserved cells were thawed and
combined with the re-stimulated cells for the infusion product. The cryopreserved T cells
were majority CD8+ prior at day 9 post-stimulation, and the combined product infused
was also majority CD8+ with increased frequency of CD4+CD8+ cells (Figure 4.8d,e).
2.18x106 total T cells/kg were infused IV. The number of CAR T cells was unable to be
determined, as the soluble anti-canine CD3 antibody in culture prevents accurate
detection of CAR surface expression for at least 9 days after addition (Figure 4.8f).
Peripheral counts of CD5+ T cells and CD79a+ B cells decreased dramatically during
pre-conditioning, but mostly recovered by day 11 post-infusion (Figure 4.9a). Peripheral
T cell counts were increased compared to the initial screen 16 days prior to infusion
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through day 50 post-infusion, peaking at 64% above screening baseline at day 25 postinfusion and suggesting a boost from our infused product. From day 11 through 46 postinfusion, increases in peripheral CD5+ T cell numbers coincide with decreases in
peripheral CD79a+ B cells, and vice versa, indicating a period of dynamic equilibrium
following infusion. However, the peripheral blood remained overwhelmingly CD79a+ by
frequency through day 50 post-infusion, and the target lymph node shifted further in
favor of CD79a+ B cells over the same time (Figure 4.9b,c). The frequency of CD4+ and
CD8+ cells among CD5+ T cells remained stable in the lymph node with a CD4+
majority, while there was a trend toward increasing CD8+ and decreasing CD4+
frequencies in the peripheral blood over the 50 days post-infusion (Figure 4.9d,e). CD28
expression amongst peripheral blood CD8+ T cells increased immediately following
infusion before returning to baseline, while in the lymph node both CD4+ and CD8+ T
cells have a decrease in CD28+ frequency at day 11 post-infusion followed by a rebound
that lasts until day 50 post-infusion (Figure 4.9f,g). qPCR showed evidence of the CAR
gene in the peripheral blood for 11 days post-infusion, and intermittently in the lymph
node including a peak at day 50 post-infusion (Figure 4.9h). In both the peripheral blood
and the lymph node, a small population of cCD20-CD79a+ B cells became noticeable
post-infusion and grew to 4.33% of peripheral blood CD79a+ B cells and 6.15% of
lymph node CD79a+ B cells by day 50 post-infusion (Figure 4.10a).
On day 46 post-infusion, the patient’s disease had progressed, and the patient was treated
with prednisone, followed by L-asparaginase and lomustine on day 50 post-infusion. The
patient continued on lomustine until progression, and was switched to doxorubicin
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treatment on day 92 post-infusion. Samples taken during follow-up visits to the hospital
for chemotherapy revealed that 65.82% of peripheral blood CD79a+ B cells and 89.10%
of lymph node CD79a+ B cells were cCD20- at day 89 post-infusion (Figure 4.10b). At
day 106 post-infusion, the few remaining peripheral B cells (326 cells/μL blood
compared to 26875 cell/μL blood at day 50 post-infusion, 5% of PBMCs) no longer had
distinct cCD20 staining. At day 138 post-infusion, 98.5% of lymph node B cells were
cCD20- compared to 93.4% of peripheral blood B cells; the cCD20+ population that
appeared is small in cell size and granularity, whereas the cCD20- B cells increased in
size and granularity, suggesting that they had begun blasting again (Figure 4.10c). At day
162 post-infusion, the patient was once again leukemic with circulating CD79a+ B cell
blasts; over 99.5% of the peripheral blood and lymph node CD79a+ B cells are cCD20-,
indicative of an antigen-negative, CAR therapy-refractory relapse. Pathology report at
this time described the malignant cells as "intermediate to large, immature lymphoid cells
with granular to finely granular chromatin and visible, medium-sized nucleoli." The
patient is continuing to be monitored and, as of April 18th, 2017, is 166 days postinfusion.
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Figure 4.1. CD28 expression and stimulus response of canine T cells taken from healthy
and diseased dogs. (a) Frequency of CD28+ cells among CD4+ or CD8+ live
lymphocytes taken from healthy or diseased dogs as measured by flow cytometry. Bars
represent means ± SEM. (b) PBMCs from a healthy (blue) or the two diseased dogs (red
and green) were stimulated with either aAPCs (solid) or Beads (dashed) for 8 days and
fold change calculated. (c) Frequency of CD28 expression among CD4+ and CD8+ live
lymphocytes, as measured by flow cytometry, from the diseased dogs over time postaAPC stimulation.
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Figure 4.2. Growth advantage of aAPC stimulus is cell-intrinsic through contactdependent and –independent mechanisms. (a) PBMCs from three healthy dogs were
cultured with Beads, K562s expressing human CD32 and loaded with agonistic anticanine CD3 and CD28 antibodies, K562s expressing human CD32 and canine CD86 and
loaded with agonistic anti-canine CD3 antibody, or left unstimulated, and lymphocytes
were counted at the end of culture. Bars represent means ± SEM. (b) CFSE-labeled
PBMCs from three healthy dogs were cultured in a transwell plate with Beads alone in
the lower chamber, Beads in the lower chamber and K562s expressing human CD32 in
the upper chamber, or Beads and K562s expressing human CD32 in the lower chamber;
CFSE peaks of live lymphocytes four days after stimulation shown with the three stimuli
for overlaid for each dog. (c) aAPCs were stained with an isotype (grey-filled) or antiCD58 antibody (black line). (d) qRT-PCR analysis of GZMB expression at day 7 poststimulation with Beads. Expression is compared to the no cytokine condition. *p < 0.05
as measured by Dunn's multiple comparison test following one-way ANOVA.
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Figure 4.3. Growth and activation comparison of canine T cells stimulated with Beads or
aAPCs. CFSE-labeled enriched PBLs from four healthy dogs were stimulated with
aAPCs with agonistic anti-canine CD3, Beads, ConA, or left unstimulated, and were
supplemented with rhIL-2 and rhIL-21 every other day. (a) Growth curves of all four
conditions, means ± SEM represented and statistical comparisons only at day 6 poststimulation shown. (b) Responder frequency of CD5+ T cells under all four conditions
over time post-stimulation, means ± SEM represented and statistical comparisons only
between Beads and aAPCs shown. (c,d) MFI of CD25 expression among CD5+ T cells at
each mitotic division at (c) day 1 and (d) 2 post-stimulation. In all cases, * p <0.05, ** p
<0.01, and *** p <0.001 as measured by Bonferroni post-tests following two-way
ANOVA.
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Figure 4.4. Increased lentiviral transduction efficiency of Bead-responsive cells than
aAPC-stimulated cells. Enriched PBLs from three healthy dogs were stimulated with
aAPCs and agonistic anti-canine CD3 and infected with pELxPS GFP lentivirus 4 days
later, or incubated with Beads and bound cells were cultured and infected with pELxPS
GFP lentivirus 1 or 2 days later. After 7 days of culture, live CD5+ cells were analyzed
by flow cytometry for GFP expression. (a) Flow plots of live CD5+ T cells, with each
row representing a donor, as well as graphs of (b) %GFP+ T cells and (c) MFI of GFP+ T
cells with means ± SEM represented.
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Figure 4.5. Phenotype of Canine T cells cultured with rhIL-2 and rhIL-21 or rhIL-7 and
rhIL-15. Enriched PBLs from four healthy dogs were stimulated with Beads and
supplemented with rhIL-2 and rhIL-21, rhIL-7 and rhIL-15, or no cytokines every other
day for 14 days. (a) Growth curves of the three conditions over time, means ± SEM
represented. (b,c) Frequency of (b) CD4+ and (c) CD8+ cells among live CD5+ cells
over time, means ± SEM represented. (d-g) Donor-matched (d,e) CD62L and (f,g) CD27
expression among (d,f) CD5+CD4+ and (e,g) CD5+CD8+ T cells. Lines in d-g connect
results from the same donor under different conditions. * p <0.05, ** p <0.01, and *** p
<0.001 as measured by Bonferroni post-tests following two-way ANOVA.
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Figure 4.6. Gene expression of Canine T cells cultured with rhIL-2 and rhIL-21 or rhIL-7
and rhIL-15. Enriched PBLs from four healthy dogs were stimulated with Beads and
supplemented with rhIL-2 and rhIL-21, rhIL-7 and rhIL-15, or no cytokines every other
day. qRT-PCR performed on cDNA synthesized from RNA harvested at day 7 and 14
post-stimulation. Upper, Data normalized to GAPDH expression, and gene expression of
rhIL-7 and rhIL-15 cultured T cells compared to rhIL-2 and rhIL-21 cultured T cells.
Means ± SEM represented. Lower, relative quantitation compared to GAPDH of select
genes shown for individual donors, lines connecting results from the same donor under
different conditions. ** p <0.01 as measured by Bonferroni post-tests following two-way
ANOVA.
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Figure 4.7. Design and function of cCD20-8-BB-ζ canine CAR T cells ex vivo. (a)
Diagram of cCD20-8-BB-ζ construct. (b) Amino acid sequence of CAR construct, colorcoded by domain as in a. (c) Nucleotide sequence of codon-optimized CAR construct. (d)
CAR surface expression among live CD5+ cells measured by flow cytometry before and
after 1, 2, and 3 co-cultures with irradiated CLBL-1 cells at a 1 T cell to 1 CLBL-1 ratio.
(e) Fold change in CAR T cells numbers calculated from total cell counts measured by
trypan blue exclusion and the frequency of CD5+CAR+ cells among live cells measured
by flow cytometry. Blue lines represent healthy donors (cCD20-8-BB-ζ), red line
represents donor in remission (cCD20-8-BB-ζ), and green represents cCD20-8-28-ζ CAR
T cells from Figure 3.3f. (f) Lysis of irradiated GFP-Luciferase-expressing GL-1 cells
with and without cCD20 overnight co-culture at varying T cell to Target ratios, as
calculated from luminescence of triplicate wells (means ± SEM represented) normalized
to target cells alone and compared to culture with non-transduced T cells from the same
donor.
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Figure 4.8. Characterization of Patient 429-006’s infusion product. (a,b) Frequency of
CD5+ cells among live cells (a) before and (b) after sorting. (c) CD79a expression on
live cells from the peripheral blood at the time of blood draw as measured by flow
cytometry. (d,e) CD4 and CD8 expression on live CD5+ T cells as measured by flow
cytometry (d) at the end of initial culture of 9 days and (e) in the combined product at the
time of infusion. (f) Flow plots of surface staining for the CAR on live transduced canine
T cells of a healthy donor 7, 8, and 9 days after addition of aAPCs with agonistic anticanine CD3 antibody.
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Figure 4.9. Peripheral blood and lymph node composition of Patient 429-006 following
CAR T cell infusion. (a) Absolute numbers of CD79a+ (blue line, right axis) and CD5+
(red line, left axis) cells over time relative to infusion, calculated from flow cytometry
and CBC. (b,c) Frequency of CD79a+ (blue line) and CD5+ (red line) cells among live
cells in the (b) peripheral blood and the (c) right prescapular lymph node as measured by
flow cytometry over time relative to infusion. (d,e) Frequency of CD4+ and CD8+ cells
among live CD5+ cells in the (d) right prescapular lymph node and (e) peripheral blood
measured by flow cytometry over time relative to infusion. (f,g) Frequency of CD28+
cells among live CD4+ or CD8+ cells in the (f) peripheral blood and (g) right prescapular
lymph node measured by flow cytometry over time relative to infusion. (h) Copies of
integrated CAR gene per μg of genomic DNA in the peripheral blood (blue line) and right
prescapular lymph node (red line) over time relative to infusion, as measured by qPCR.
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Figure 4.10. Changes in cCD20 expression among Patient 429-006’s B cells following
CAR T cell infusion. (a) Frequency of cCD20- cells among live CD79a+ cells in the
peripheral blood (blue line) and right prescapular lymph node (red line) as measured by
flow cytometry over time relative to infusion. (b) cCD20 and CD79a expression of live
cells from the peripheral blood and right prescapular lymph node at day 89 post-infusion
as measured by flow cytometry. (c) Overlaid FSC and SSC plots of cCD20- (red) and
cCD20+ (blue) live CD79a+ cells in the peripheral blood at day 138 post-infusion as
measured by flow cytometry.
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Discussion
While evidence of decreased expression of CD28 on CD4+ T cells of canine patients with
end-stage lymphoma is limited, the functional consequence of their ability to respond to
Beads or aAPCs is stark. This is particularly interesting in light of the fact that many
human CLL patients are unable to participate in CAR T cell trials due to their inability to
expand using human-specific beads (Fraietta et al., 2016; Porter et al., 2015). Combined
with observations in vivo from Chapter 3, this strengthens the rationale for using
frequency of CD28+ T cells as a marker of health in the canine T cell compartment.
While the relationship may not be direct, and CD28 expression may be correlated to
something else that has a greater impact on T cell functionality and survival, it is the best
proxy available within the repertoire of markers for which there are canine-specific
antibodies. In humans, levels of CD28 expression on CD8+ T cells decrease with
increased differentiation as well as the age of the host (Leitner et al., 2015); it is possible
that this decrease among canine CD4+ T cells may be associated with these same factors
upon further investigation, but the patients that we treated were not much older than our
healthy donors. That these CD28+ T cells are potentially the best starting T cell
population from which to make a product is underlined by the potent activation and
proliferation response elicited by the Beads. Early cell division and overall population
growth are decoupled in our stimulus systems, as evidenced by the superior expansion by
the aAPCs; the likely scenario is that T cells that respond to the Beads do so rapidly and
strongly and those that do not die off in culture, increasing the responder frequency when
examining only live cells as time progresses, while the T cells that would not respond to
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the Beads are “rescued” by the aAPCs and eventually divide later on. Potential
mechanisms for aAPC-mediated “recovery” of canine T cells, and possible ways to take
advantage of them, are discussed in Chapter 5.
Use of rhIL-7 and rhIL-15 instead of rhIL-2 and rhIL-21 seems to maintain more
memory-like cells based on the increased frequency of CD62L+ cells. Interpretation here
is limited, as some of the commonly used surface markers to differentiate memory and
effector subpopulations are cannot be accurately measured in canine T cells; caninespecific or cross-reactive antibodies to CD44, CCR7, CD45RA, CD45RO, CD95,
CD127, and KLRG1 are either lacking or unreliable in our use. Regardless, that these
markers identify the same populations in dogs as they do in humans and mice would need
to be validated. While qRT-PCR is limited when examining bulk T cells, the increase in
CD62L expression matches our flow observations. The decrease in GZMB and PRDM1
suggests an overall shift within the population away from effector cells. The decrease in
BCL6 expression is puzzling, as it works in opposition with PRDM1 in mice and humans,
but mRNA levels do not correlate with Bcl6 activity, as there is significant posttranscriptional and post-translational control involved (Crotty et al., 2010). The initial
increase and eventual decrease in both EOMES and TBX21 mRNA is difficult to interpret
from a mixed pool of T cells, especially in light of the many roles each of these
transcription factors plays, but it is worthy of deeper investigation considering their key
part in T cell function and exhaustion. Overall, it would appear that culture of canine T
with rhIL-7 and rhIL-15 is associated with decreased terminal differentiation, just as it is
in human T cells.
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Preliminary ex vivo functional assays with the cCD20-8-BB-ζ CAR in canine T cells
demonstrate their impressive proliferative capacity in response to repeated target
challenge. Compared to the limited expansion of the canine cCD20-8-28-ζ CAR T cells
ex vivo, this suggests that the BB-based construct overcomes some of the limitations of
the CD28-based construct, just as observed in human CAR T cells (Kawalekar et al.,
2016; Long et al., 2015).
There were many factors that were different with Patient 429-006 compared to the four
patients described in Chapter 3 – sorting of the T cells, different stimulus, different
cytokines used in culture, shorter culture time, that the patient was profoundly leukemic,
that the pre-conditioning chemotherapy had a significant lymphodepletive effect, a
different co-stimulatory domain within the CAR construct – so it is impossible to credit
the difference in outcome on any single change. However, the goal was to generate a
better therapy overall, including whatever modifications at each step that may have
contributed to that. The circulating malignant B cells rebounded following the end of
chemotherapy pre-conditioning, and their numbers were never dramatically reduced until
rescue chemotherapy was begun at day 46 post-infusion. Nevertheless, the presence of
the CAR gene in the target lymph node 50 days post-infusion is encouraging, and qPCR
results for peripheral blood and lymph node aspirate samples following that timepoint are
pending. The most stunning outcome was the loss of cCD20 in both the circulating and
lymph node B cells, which preceded rescue chemotherapy. It is possible that there was a
spontaneous loss of cCD20 expression in some of the malignant cells or a second
transformation occurred among cCD20- B cells, but the simplest explanation of this
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observation is immune pressure selecting against cCD20 expression, and that the cCD20targeting CAR T cells which were still present at day 50 post-infusion were mediating
this. The similarities in the pathology report descriptions at diagnosis and 162 days postinfusion also support this. That the B cell populations became overwhelmingly cCD20- in
the months that followed could be attributed to two potential scenarios: continued
pressure from the CAR T cells, or the malignant population derived from the cCD20clone had a proliferative advantage. Determining whether the CAR T cells persisted,
measured by forthcoming qPCR data, will help clarify this. Antigen escape has been
observed in human CAR T cell trials targeting CD19 in B cell leukemias; in those cases,
CD19 is not lost, but instead a splice variant that does not include the epitope for the antiCD19 scFv within the CAR is expressed (Sotillo et al., 2015). Additionally, loss of CD20
expression among human non-Hodgkin’s lymphomas that have relapsed following
CD20-targeting antibodies such as rituximab is common, and these can also be in the
form of epitope-negative splice variants (Gamonet et al., 2016; Haidar et al., 2003).
Efforts to sequence the ostensibly cCD20- B cells are underway to determine whether we
have encountered a similar phenomenon, and samples of the cCD20- cells and the
original tumor are being submitted for PARR to confirm that the cCD20- cells are clonal
and are derived from the original tumor.
Altogether, these steps have led to a current canine CAR T cell therapy protocol that,
while still unable to elicit a clinical remission, appears to be forcing specific tumor
immunoediting in order to escape elimination, just as in humans (Sotillo et al., 2015).
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General conclusions and potential avenues for therapy improvement are discussed in
Chapter 5.
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CHAPTER 5: Conclusions and Discussion

CAR T cell therapy is not between 500 and 600 amino acids long. It is the patient, their
disease, and their history of prior therapy. It is how the T cells are isolated from the
patient, and what they experienced while in there. It is how these T cells are stimulated
and fed, how they are grown and for how long. It is when and how the CAR is expressed,
by what delivery, for how long, and at what level. It is how these T cells are preserved,
and what has happened to the immune and tumor environment within the patient before
they are infused back in. It is how these T cells circulate and traffic into tissues, it is how
they expand and contract, metabolize and differentiate, survive and die. It is how the T
cells, the tumor, the tissues, and the other immune cells of the patient all interact with
each other.
CAR T cell therapy is re-creating the essentials of T cell immunobiology, but with a
synthetic antigen receptor. Any attempt at modeling CAR T cell therapy, or any
immunotherapy, must recapitulate all of these factors and more to have a hope at being
accurate and predictive. We believe that dogs and the treatment of their spontaneous
malignancies are the best potential model we have for human patients, and that the
advances described in this thesis have made this goal attainable. Indeed, in treating just
six dogs over the course of two years, our results have recapitulated the effects of patient
chemotherapy, the development of anti-CAR immune responses, the CAR T cell
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persistence issues, and the antigen-negative relapses that were seen after years of human
clinical trials, and had not been predicted in mouse models.
This chapter consists of three major themes: conclusions of our findings,
recommendations for near-term investigations that follow our observations, and
suggestions for long-term future directions with a discussion of broader implications.

Obtaining Better Initial Cell Products from Patients
We have found in dogs, as in humans, that prior cytotoxic chemotherapy can damage the
T cell compartment before it is isolated from the patient to be expanded for the
therapeutic product. While the proliferative capacity of the canine T cells recovers as the
time of isolation moves farther and farther away from the last dose of chemotherapy, it
shortens the time available to generate a CAR T cell product before the patient relapses
or the disease reaches a stage of rapid progression that does not allow a window of
opportunity for the CAR T cells to expand in vivo and establish control. One potential
solution for this is to collect blood to generate a product from newly-diagnosed canine
patients when they are unexposed to chemotherapy, and generate and preserve the
product while the patient receives CHOP chemotherapy until they are in clinical
remission; this would allow the initial T cells to be unexposed to harmful chemotherapy,
and infusion of CAR T cells during remission would allow the CAR T cells to establish
themselves in the patient and expand against normal B cells until the malignant clone
resurfaces; as greater than 80% of canine B cell lymphoma patient relapse in less than a
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year following CHOP-induced remission, our measurement of clinical efficacy would be
disease-free survival. Another option is the use of the BTK inhibitor ibrutinib; studies in
humans with CLL have found that patient T cells are similarly hindered in their
expansion, but that inclusion of ibrutinib in the patient anti-CLL treatment prior to
apheresis for T cell collection markedly improved the health of the T cells (Fraietta et al.,
2016; Ruella et al., 2016). The mechanism appears to be both counteracting
immunosuppression by the malignant B cells, as well as direct positive effects on the T
cells. In particular, ibrutinib treatment was associated with decreased expression of the
inhibitory ligand CD200 on the malignant B cells and decreased expression of inhibitory
receptors on the T cells; ibrutinib also appears to inhibit ITK in T cells, pushing them
from a Th2 phenotype to a more effective anti-tumor Th1 phenotype. Ibrutinib has been
tested in canines before, with signs of cross-species bioactivity (Honigberg et al., 2010).
We currently collect canine T cells through Ficoll gradient separation of whole blood. In
addition to contamination with other components of the PBMC compartment and
platelets, as well as dead cells due to Ficoll’s toxicity, a significant number of canine
neutrophils migrate at PBMC level in Ficoll with the commercially available specific
gravity of 1.077 (Wunderli and Felsburg, 1989). In Chapters 2 and 3, we enriched for live
PBLs by culturing the collected cells on tissue culture plates overnight, allowing
platelets, dead cells, and adherent monocytes to stick to the plate, before harvesting cells
remaining in suspension for stimulation. Interestingly, two very recent studies in the field
of human CAR T cells therapy have also focused on enriching for lymphocytes and
avoiding myeloid-derived suppressor cells, using elutriation and the same tissue culture
132

plate-adherence method that we used (Stroncek et al., 2017; Stroncek et al., 2016).
Nevertheless, residual malignant cells or myeloid-derived suppressor cells could remain
in culture and hinder ex vivo T cell expansion. To select for T cells specifically, we also
developed a negative selection protocol by MACS, depleting CD11b, CD11c, CD14, and
CD21-expressing cells, that resulted in 95% CD5+ cell purity for a trial patient that was
treated too recently to include in Chapter 4. Flow-sorting is highly efficient for purity, but
expensive for the required cell number yield. However, sorting specifically for CD28+ T
cells could be an attractive option, especially from patients that may have a low
frequency of them, given their potency that we have observed so far.

Understanding ex vivo T cell Recovery
Understanding the consequences of CD28 expression on canine T cells has traced our
work from our earliest in vitro experiments, when some canine donor PBMCs did not
respond to Bead stimulation, to our in vivo immune monitoring, where increased CD28
expression in T cells in the patient is associated with disease control. Our preliminary
data shows lowered frequency of CD28-expressing CD4+ T cells in dogs with late-stage
lymphoma, and a differential response to Bead or aAPC stimulus. The ability to not only
expand T cells from a Bead-refractory population, but also increase CD28 expression
among those cells, is a particularly exciting feature of the aAPCs. Examining a larger
cohort of canine patients with various stages of malignancy and different amounts of
chemotherapy treatment and comparing to age-matched healthy canine donors their levels
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of CD28 expression as well as their ability to respond to Beads or aAPCs is an obvious
next step to confirm this observation. This rationalizes identification of stimulatory
factors on the aAPCs and its parental cell line, the K562. Our first candidate is the costimulatory ligand CD58, which we found to be expressed on K562 cells; gain and loss of
function experiments using recombinant CD58 bound to CD3/CD28 Beads and using a
CD58-blocking antibody with aAPCs are already planned. While aAPCs are superior in
their stimulatory abilities and, as a cell line, a cheap and self-renewing resource, they are
an additional cell in culture to uptake virus, and use of a xenogenic cell line in CAR T
cell product manufacturing poses issues for GMP compliance that magnetic beads do not.
The eventual generation of an aAPC-on-a-Bead would be breakthrough for both canine
and human CAR T cell therapy, as human patients are often excluded because of
inadequate expansion with human Beads. This is particularly fitting as K562s were
identified first as an aAPC of choice for human T cells, and their adaptation to canine T
cells has led to findings that can improve human T cell expansion.
We described two iterations of cytokine supplementation for canine T cell culture, use of
rhIL-2 and rhIL-21 and the use of rhIL-7 and rhIL-15. Exploration of other cytokines, or
combinations of more than two cytokines could very easily produce a much more potent
milieu for T cell growth and preferred differentiation (Xu et al., 2016). Another
consideration is the use of canine cytokines instead of human ones, as several have
become commercially available recently. Use of canine IL-2 resulted in the growth of
roughly twice as many canine NK cells in ex vivo culture than human IL-2, suggesting
stronger species-specific bioactivity (Foltz et al., 2016).
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Opportunities for Improved CAR Design
While CAR constructs using CD28 or 4-1BB co-stimulatory domains were both used in
our in vitro experiments, they were never compared in the same conditions in T cells
from the same donors. Efforts to confirm the differences and advantages of each in
canine T cells are worthwhile, as they may be different from the findings in human
studies. To perform this, isolated and purified peripheral T cells could be electroporated
with mRNA encoding either CAR, as in Chapter 2, and cytokine production,
proliferation, and differentiation following signaling through either CAR could be
compared within each donor; this would allow assessment of the effects of the CAR
independent of culture conditions or variable expression levels following transduction.
Another compelling study would be treating canine patients with both cCD20-8-28-ζ and
cCD20-8-BB-ζ CAR T cells, and track the expansion, contraction, and engraftment of
either population among the peripheral blood and various tumor sites over time by qPCR.
We have already designed primers that would differentiate between the two CAR
constructs, and are actively preparing for this next trial.
There has been a significant amount of debate surrounding what the success of CD19targeting CAR T cells in humans is predicated on, especially since its success rate is an
outlier among CAR T cell therapy targets. There are two major competing, albeit not
mutually exclusive, hypotheses: that it is the CD19 target, or the CD19-targeting scFv. In
case of the former, CD19 is restricted to the B cell lineage, so it can be targeted without
concern for off-tumor on-target lethal toxicities, and constant low-level replenishing of
CD19+ non-malignant target cells keeps the CAR T cells primed against relapse;
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additionally, trafficking to sites that contain the CD19 target through circulation, tissues,
lymph nodes, B cell-producing niches of the bone marrow, and others put the CAR T cell
in prime locations for receiving survival signals. Evidence for the latter is that scFvs
naturally aggregate, and expression on the cell surface while attached to signaling
domains leads to constant self-signaling and eventual self-exhaustion (Whitlow et al.,
1994). However, the commonly used anti-human CD19 scFv FMC63 does not have this
“sticky” characteristic; in fact, swapping out the framework regions of FMC63 –
retaining its specificity – with those of a “sticky” anti-GD2 scFv leads to exhaustion and
lack of efficacy (Long et al., 2015). Based on these two hypotheses for the success of
anti-CD19 CAR therapy, there are two avenues to explore. First is to determine whether
the cCD20 scFv we use in our CAR constructs leads to self-signaling. Secondly, we are
in the process of developing an anti-canine CD19 antibody and screening for canine
CD19-reactive scFvs among phage libraries.
Another major consideration in our choice of targeting moiety is the species of origin.
While B cell-targeting CAR T cells will not run into the problem of anti-murine
antibodies being developed against the scFv if they are successful in B cell clearance,
targeting other tumors in humans has led to the development of HAMA and we have
observed the development of CAMA when B cell clearance is not achieved (Kershaw et
al., 2006; Maus et al., 2013). Alteration of the scFv to match the patient species will
avoid this outcome, and we are currently assembling resources for a canine phage library.

136

Canine Patient Pre-Conditioning
Lymphodepletion, particularly the regimen used, has been found to be critical for success
in human CAR T cell therapy (Turtle et al., 2016). Not only does it reduce tumor burden
in hematological malignancies and decrease established regulatory T cells and myeloidderived suppressor cells that can hinder therapy efficacy, the reduction of competing T
cells aids homeostatic expansion and engraftment of the infused CAR T cells. In only one
patient, 429-006, can we say that we made any real effect on the lymphocyte population
by the time of infusion. It is unclear whether it is because the patient’s cells were
particularly susceptible, or that the combination of vincristine and cyclophosphamide in
that short period of time was effective.
The pre-conditioning chemotherapy regimen of choice in human therapy has been a
combination of cyclophosphamide and fludarabine (Porter et al., 2011; Turtle et al.,
2016). While cyclophosphamide is commonly used in canine patients, fludarabine has
only been used in an experimental canine bone marrow transplant models (Gyurkocza et
al., 2009). The combination of the two has been a double-edged sword in human therapy:
the magnitude of its efficacy on treatment success is matched only by the severity of its
side effects. While it has led to remarkable expansion and efficacy of human T cells in
vivo and prevented anti-CAR immune responses, it has also increased the likelihood and
severity of cytokine release syndrome (Turtle et al., 2016). The role of canine patients as
companion pets gives the side-effects of CAR T cell therapy and its associated preconditioning unique consideration, as owners are especially sensitive to quality of life
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when determining end of care. This challenge in privately-owned animals may pressure
the field to focus on determining the minimum effective dose – in all species.

Efficacy and Safety in Canine CAR T Cell Therapy
Clinical response and CRS appear to go hand-in-hand in human CAR T cell therapy, and
whether that toxicity is necessary for efficacy is an area of open debate. We have
observed neither yet in our canine patients, suggesting perhaps that this correlation is
across species. Our patient data that we have collected over the course of this thesis
suggest that we are getting closer to obtaining a clinical response, and possibly CRS
along with it, but several steps are necessary before we can claim that canine CAR T cell
therapy is finally on par with human CAR T cell therapy. Some of these improvements
have already been mentioned in discussions in other chapters as well as this one. Based
on observations from our canine patients as well as human patients, a theoretical ideal
protocol would consist of the following. T cells would be isolated and purified from
patients that have not yet received chemotherapy, to avoid negative effects of
chemotherapy and other suppressive cells on the T cells. These would undergo a short
expansion period, supplemented with aAPCs and possibly ibrutinib to recover these cells,
and would be cultured with rhIL-7 and rhIL-15 to maintain central and stem-like memory
populations. To achieve a target cell dose in the range 106 CAR T cells/kg, a larger
starting number of T cells could be used; alternatively, technological advancements for
rapid human T cell growth, such as a wave-bioreactor system or G-Rex flasks, could be
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used in lieu of standard tissue culture flasks. These T cells would express a cCD20-8-BBζ CAR, ideally in which the scFv is of canine origin to avoid anti-CAR immune
responses in vivo and has been shown to not self-stick. The patient would be preconditioned with cyclophosphamide and fludarabine, to reduce tumor burden and
suppressive immune cells as well as create a niche for the CAR T cells to engraft and
expand in. The reduction in tumor burden will also be important because of the
aggressiveness of canine lymphoma once it progresses, and the time for a clinical
response in treating human B cell lymphomas with CAR T cells is on the order of
months. To counteract any CRS, the cross-reactivity of the human IL-6R blocking
antibody tocilizumab, standard of care now for ameliorating CAR-mediated CRS in
humans, would need to be validated in dogs or a new canine-specific blocking antibody
would need to be developed. A model of how several of these steps are expected to affect
the clinical outcome is shown in Figure 5.1.

Genetic Modification of Primary Canine T Cells
Lentiviruses have been found to naturally infect primate, equine, bovine, ovine, caprine,
and even feline species, but no naturally-occurring canine infection with lentivirus has
been discovered. In fact, exogenous retroviruses as a whole have been curiously absent
from canine pathology. Nevertheless, we have been able to infect primary canine T cells
with lentivirus, albeit at much lower efficiencies than primary human T cells in head-tohead comparisons that we have performed. We pseudotype with the VSV-G envelope,
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which should allow broad mammalian tropism due to its binding of the LDL receptor
(Finkelshtein et al., 2013); while cells of hematopoietic origin are known to express low
levels of surface LDL receptor while resting, it rapidly increases upon stimulation, and
the canine T cells are almost entirely CD25+ by the time we infect with lentivirus
(Amirache et al., 2014). This would suggest that the major hurdle in successful
transduction is post-entry. mTOR inhibitors have been suggested to alleviate this block,
but preliminary testing we have performed with rapamycin and Torin1 has been limited
by toxicity (Wang et al., 2014). We have also attempted transduction with
gammaretroviruses using the MMLV and MSCV promoters, but head-to-head
comparisons with lentivirus showed decreased transduction efficiency, and we expect
that they face the same canine-intrinsic post-entry challenge.
The level of CAR expression in a cell is crucial to its function. Too little, and there is
little dimerization upon antigen-binding and no productive signal transduction. Too
much, and the CAR will aggregate on the cell surface on its own, and self-signal without
antigen. While the choice of promoter plays a significant role in the expression level of
the transgene, the location in the genome where the lentivirus or gammaretrovirus
integrates is just as, if not more important. Entry into a silenced site is unproductive, and
insertion into functional exons could be deleterious in many respects. The ideal level of
expression and gene control would match the T cell’s own endogenous antigen receptor.
Combined with the advent of CRISP/Cas9 technologies, this presents a unique
opportunity: disruption of the TCR locus with CRISPR, followed by using the CAR
transgene as a donor sequence to insert in its place (Eyquem et al., 2017). Not only would
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this allow CAR expression to be controlled under same “Goldilocks” conditions as the
TCR, but, combined with elimination of MHC expression, this could be used to generate
allogeneic CAR T cell products that cannot perform GVHD and avoid clearance by
recipient T cells. As CRISPR gRNAs and Cas9 mRNA can be electroporated and AAVs,
which are the gene donors of choice, are used in canine disease models (Koeberl et al.,
2008), this is an attractive long-term strategy for dogs for which an autologous CAR T
cell product cannot be generated – and also one that dogs are well-suited for, given their
history of pioneering allogeneic transfers since the 1950s (Ferrebee et al., 1958).

Accurate Identification of Canine Immune Cell Populations
As particularly evident in our attempts to generate and identify canine memory T cells in
Chapter 4, the lack of available antibodies for identifying canine surface markers is a
major frustration for this field. CD5 is the canine T cell identifier of choice in no small
part because the anti-canine CD3ε antibody is of such low affinity and varying quality
batch-to-batch that it cannot be relied upon for accurate staining. There is no anti-canine
CD19, leaving an anti-CD79a antibody that stains intracellularly as the only pan-B cell
marker available for canine studies, limiting experiments on sorted live canine B cells. A
concerted effort to identify and validate potential cross-reactive antibodies among those
available for other species or to generate canine-specific ones in their absence is not only
necessary, but worthwhile. This will allow us to more accurately identify and characterize
the cells we are getting from our patients, the cells that we are growing ex vivo and
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putting back into our patients, and what they are doing in vivo – all critical for the
advancement of the canine model of therapy and, with it, human therapy.
A case in point is the identification of canine NK cells. Due to the limited markers, this is
an area of not only active exploration but also controversy in the canine field since they
cannot be readily differentiated from canine T cells (Foltz et al., 2016; Huang et al.,
2008; Michael et al., 2013). CD3 staining is unreliable, and validated anti-CD56 or antiCD16 antibodies are not available for dogs. In our own experience, we have observed a
lymphocyte population in the peripheral blood of healthy canine donors that stains
distinctly CD5low, and these cells are uniformly CD8+, CD79a-, CD28-, CD27-, and
only stain for CD3ε when permeabilized. Whether these are NK cells or a different
lymphocyte subset is unknown. Understanding what these cells are is of importance to
use for two reasons. First, these cells are in our starting cultures, even if we purify for
only CD5-expressing cells, and are likely still present in our infusion product. Second, in
the course of screening canine patients with lymphoid malignancies, we have come
across multiple patients with tumors with the same expression pattern. A canine-specific
NKp46 antibody has been recently reported, and we are in the process of obtaining it to
characterize both normal and banked tumor samples (Foltz et al., 2016).

Bringing Canine Molecular Immunology Up to Speed
Next-generation sequencing, and the precipitous drop in cost for performing it, has been
transformative for basic, translational, and clinical immunology. Tumor-specific
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mutations can be rapidly identified and exploited by whole exome sequencing, and the
expression and epigenetic profiles of even the smallest subset of cells can be
characterized by RNA-seq and ATAC-seq. However, all of this depends on a foundation
of robust and well-annotated reference sequences. In this particular capacity, canine
genetic analysis is woefully and, considering the wealth of information and opportunities
that can be derived from it at such a relatively low cost, inexcusably lacking. Raw reads,
especially from ancient dog samples used for evolutionary studies, are available, but the
NCBI canine reference genome is from a single boxer (NCBI Accession NC_006621.3)
(Frantz et al., 2016; Lindblad-Toh et al., 2005). In our own experience, the predicted
sequences for multiple canine genes from this reference genome have been inaccurate.
We and another group have independently found the same amino-acid level differences
from the reference sequence when cloning canine PD-1 (NCBI Accession
NP_001301026.1) (Maekawa et al., 2014). The predicted sequence for canine CD3ζ has
only 2 intact ITAMs, and a CAR construct including the predicted intracellular domain
sequence does not express on the cell surface (NCBI Accession XP_005623027.1); we
found at least 18 amino acid differences in the intracellular domain alone when we cloned
it ourselves from canine cDNA. These discrepancies among such a small sample size are
troubling, and we strongly encourage the generation of a more accurate and higherquality canine reference genome from many more canine donors across breeds. These
efforts can be de novo, or whole exome sequencing data of tumor and normal tissue in
comparative oncology studies can be made public.
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Concluding Remarks
Dogs have been used as a model for human immunotherapy for decades, since the days of
bone marrow transplantation studies in the mid-20th century. Using canine patients with
spontaneous malignancies, from cancers of the blood to the bone, to model CAR T cell
therapy and other cutting-edge technologies is the natural evolution of looking to our
companions for insight. It took over twenty years since the first CAR, and over ten years
since the development of anti-human CD3 and CD28 beads to grow T cells, before the
clinical success of CAR T cell therapy in humans. Our work here in dogs has mirrored
some of the successes – and many of the challenges – found in the treatment of our own
species in just over four years, and the development of canine reagents and resources is
the only barrier to further breakthrough therapies for our dogs and ourselves.
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Figure 5.1. Model of improvements for canine CAR T cell therapy. Diagram of patient
product generation and treatment, with negatively-associated factors in red and
positively-associated factors in blue.
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CHAPTER 6: Materials & Methods

Generation of cell-based artificial APCs
The human erythroleukemic cell line K562 was stably transduced with a self-inactivating
lentiviral vector, pCLPS, containing the human FcγRII (CD32) and cloned by single cell
sorting to produce Kt32 as previously described (Maus et al., 2002; Suhoski et al.,
2007). KT32 cells expressing cCD86 were generated. Briefly, canine CD86 was
amplified from cDNA derived from PHA and rhIL-2 stimulated canine PBMCs by RTPCR using gene specific primers flanked with BamHI and XhoI restriction sites. The
resulting cDNA was cloned into the pCLPS vector. Lentivirus was generated as
previously described and used to transduce KT32 cells (Parry et al., 2003; Reiser,
2000). KT32 cells expressing high levels of cell surface canine CD86 were bulk sorted to
produce KT32/cCD86, referred herein as aAPCs. aAPCs were cultured in K562 media
containing Roswell Park Memorial Institute media (RPMI) 1640 with 2 mM L-glutamine
(Mediatech, Manassas, VA), 10% heat-inactivated fetal bovine serum (Atlanta
Biologicals, Lawrenceville, GA), 10 mM HEPES (Gibco, Grand Island, NY), 1 mM
sodium pyruvate (Mediatech), 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco),
and 30 μg/ml gentamicin (Gibco), filtered through a 0.22 μm filter Stericup (Millipore,
Billerica, MA).
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Generation of anti-canine CD3/CD28 magnetic beads
Agonistic mouse anti-canine CD3 (clone CA17.2A12, ABD Serotec, Raleigh, NC) and
mouse anti-canine CD28 (clone 5B8, a generous gift of Dr. Rainer Storb) were
conjugated to magnetic tosylactivated Dynabeads (Life Technologies, Grand Island, NY)
according to the manufacturer's protocol. In brief, 25 μg of both antibodies were
incubated with 108 activated beads for 24 hours at room temperature in the presence of
sterile filtered 0.01% bovine serum albumin (Sigma-Aldrich, St. Louis, MO) to prevent
nonspecific binding. Beads were then incubated at 37°C for 4 hours to deactivate unused
tosyl-groups. Conjugated beads were stored at 4 × 108/ml in 0.1% bovine serum albumin
w/v in Dulbecco's phosphate-buffered saline (DPBS) (Mediatech) with 2 mM EDTA
(Gibco) and 0.01% sodium azide (Amresco, Solon, OH) at 4°C.

Canine PBMC isolation and T cell culture
Canine PBMCs were isolated by discontinuous density centrifugation over Ficoll-Paque
PLUS (s.g. 1.077, GE Healthcare, Uppsala, Sweden). PBMCs were washed twice in T
cell media (TCM) containing RPMI 1640 with 2 mM L-Glutamine (Mediatech), 10%
heat-inactivated fetal bovine serum (Atlanta Biologicals), 10 mM HEPES (Gibco), and
100 U/ml penicillin and 100 μg/ml streptomycin (Gibco), filtered through a 0.22 μm filter
Stericup (Millipore). Live PBMCs were enumerated by hemocytometer using trypan blue
exclusion, and plated on 10 cm diameter tissue culture dishes (Falcon, Corning, NY) at 1
× 106 cells/ml and incubated overnight at 37°C and 5% CO2. Supernatants enriched for
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viable peripheral blood lymphocytes (enriched PBLs) were collected on the following
day and cells were pelleted following centrifugation at 218g for 5 minutes. When aAPCs
were used for T cell activation and expansion, aAPCs cells were irradiated with 10,000
rads, washed in TCM, and resuspended at 5 × 105 cells/ml. Cells were co-cultured with at
a 1:2 ratio of aAPCs:enriched PBLs to a final concentration of 5 × 105 enriched PBLs and
2.5 × 105 aAPCs per ml with 0.5 μg/ml mouse anti-canine CD3. When antibodyconjugated beads were used for T cell activation and expansion, beads were washed three
times with DPBS and once with TCM before addition to enriched PBLs at a 3:1 ratio of
beads:enriched PBLs in Chapter 3, and then 4:1 in Chapters 3 and 4. During lectininduced proliferation, PBMCs were cultured with 2.5 ng/ml of concanavalin A (SigmaAldrich) with 100 U/ml recombinant human IL-2 (Gibco) added after 48 hours, unless
described otherwise. In all cases, cells were cultured at 37°C and 5% CO2 with TCM.
Where indicated, 30 U/ml rhIL-2 (Gibco) and 10 ng/ml rhIL-21 (eBioscience) were
added at the time of stimulation and every second day thereafter. Where indicated, 10
ng/mL rhIL-7 (Peprotech, Rocky Hill, NJ) and 5 ng/mL rhIL-15 (Peprotech) were added
at the time of stimulation and every second day after; for Patient 429-006, 20 ng/mL of
rhIL-7 and 10 ng/mL rhIL-15 were used.
Trial patient T cells were grown as described in Chapters 2, 3, and 4. Cell culture
supernatants at the time of harvest were submitted to the University of Pennsylvania Cell
Center Services core for mycoplasma testing; all samples returned negative. An aliquot of
each infusion product was submitted to the VHUP microbiology lab for gram stains; all
samples returned negative. Aliquots of cultured cells of the lentivirus trial patients were
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taken 3, 5, and 7 days post-infection and submitted to the University of Pennsylvania
Translational and Correlative Studies Laboratory for Replication Competent Lentivirus
testing; samples passed prior to infusion.

Flow cytometric analysis of canine cells
Where indicated, PBMCs were washed twice with DPBS, resuspended to 1 × 107 cells/ml
in DPBS, and labeled with carboxy-fluoroscein succinimidyl esterase (CFSE, 5μmol/l,
Sigma Aldrich) for 5 minutes at 37°C. Labeling was quenched with 5 volumes of TCM.
Cells were washed twice and resuspended in TCM prior to stimulation. At the time points
indicated, cells were harvested and washed in fluorescence-activated cell sorting (FACS)
buffer (1% heat-inactivated fetal bovine serum in DPBS with calcium and magnesium)
prior to surface staining with a combination of the following antibodies: APC- or
PacificBlue-labeled rat anti-dog CD4 (clone YKIX302.9, ABD Serotec), PE-labeled rat
anti-dog CD5 (clone YKIX322.3, eBioscience), PE- FITC- or AF647-labeled rat anti-dog
CD8 (clone YCATE55.9, ABD Serotec), mouse anti-dog CD20 (clone 6C12, Invivogen,
San Diego, CA) with BrilliantViolet421- or AlexaFluor488-labeled goat anti-mouse IgG
secondary (clone Poly4053, Biolegend or Life Technologies), eFluor660-labeled mouse
anti-dog CD25 (clone P4A10, eBioscience), PECy7-labeled Armenian hamster antimouse CD27 (clone LG.7F9, eBioscience), PECy7-labeled mouse anti-human CD45
(clone HI30, Biolegend, San Diego, CA), FITC-labeled mouse anti-human CD62L (clone
FM46, ABD Serotec), and the cell viability dye 7-AAD (Biolegend). Following surface
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staining, cells were washed twice in FACS buffer and fixed in 1% paraformaldehyde
(Ted Pella, Redding, CA). Where indicated, cells were permeabilized with 0.1% saponin
(Sigma Aldrich) post-fixation and stained with a cross-reactive APC-labeled mouse antihuman CD79a antibody (clone HM57, BD Biosciences, San Jose, CA). Surface detection
of the CAR was performed by labeling with a biotinylated rabbit anti-mouse IgG H+L
antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) followed by fluorconjugated streptavidin secondary (BD Biosciences) prior to all other surface staining.
T cells were defined by expression of CD5, B cells were defined by expression of
CD79a, and aAPCs were defined by expression of human CD45. For flow cytometric
enumeration, labeled samples were spiked with a known number of CountBright Beads
(Life Technologies) prior to acquisition, and cell numbers were calculated based on bead
recovery. Acquisition was performed on a FACSCalibur, FACSCanto II, or LSR Fortessa
flow cytometer (BD Biosciences) and data was analyzed using FlowJo software version
X (Treestar, Ashland, OR). Patient 429-006 cells were sorted for 7-AAD-CD5+ on a
FACS Aria.

Cell lines
K562 cells, K562 cells expressing human CD19 (K562.hCD19), and the human primary
pancreatic adenocarcinoma cell line BxPC3.hCD19 were kindly provided by Dr. Carl
June. The murine fibroblast line 3T3 was kindly provided by Dr. Jonathan Maltzman.
GL-1 cells expressing GFP-CBG-Luciferase with and without cCD20 were kindly
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provided by Dr. Avery Posey. Jurkat cells were kindly provided by Dr. Daniel Powell,
and Jurkat cells expressing the hCD19-8-ζ CAR were kindly provided by Dr. Michael
Milone. To generate canine CD20 (cCD20) expressing target cell lines, cCD20 was
amplified from PBMC cDNA and cloned into pCLPS. The cCD20 transgene and the
IRES-GFP reporter cassette following the transgene were under the control of a CMV
promoter. Lentivirus was generated as previously described, and concentrated
supernatant was used to infect K562 and 3T3 cells to generate cCD20-expressing K562
cells (K562.cCD20) and 3T3 cells (3T3.cCD20).
3T3 and 3T3.cCD20 cells were grown in Dulbecco's modified essential medium
(Mediatech) with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals), Lglutamine (2 mM), and 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco), filtered
through a 0.22 μm filter Stericup (Millipore). All K562 cell lines were grown in K562
media, while BxPC3.hCD19, Jurkat cell lines, canine malignant B cell lines 17–71, GL-1,
and canine B cell lymphoma cell line CLBL-1 were grown in TCM. All cell lines were
cultured at 37°C and 5% CO2.

qRT -PCR
Total RNA was extracted using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA).
Reverse transcription was performed using random hexamers and Superscript II reverse
transcriptase according to the manufacturer's instructions (Life Technologies). Primers
were designed using Primer3 software version 0.4.0 (http://frodo.wi.mit.edu/primer3/)
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with the maximum self-complementarity score set at 5 and the maximum three selfcomplementarity score set to 0 to minimize primer-dimer formation. Primers are as
follows:
BCL6
Forward: 5'-GTTCTGCATCCTCCTGGACTT-3'
Reverse: 5'-GTACATCGCCGTAGCCATCA-3'
CCR7
Forward: 5'-GATGAAGGAGGCTTGAGATGG-3'
Reverse: 5'-TGCTGCAATAGGGATCAGGAG-3'
CD44
Forward: 5'-CACCTTCCAACTGCATACCC-3'
Reverse: 5'-CCGATGAGTCGTGGTCTTTG-3'
CD62L
Forward: 5'-TCATGTAGCAACCACGGAGA-3'
Reverse: 5'-GGCTCACACTGAATCACGAA-3'
EOMES
Forward: 5'-AATCGGGCTGTGAAGATTTGAG-3'
Reverse: 5'-GCCACTCTGGGATTCTCCTT-3'
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GAPDH
Forward: 5′-GGCAAATTCCACGGCACAGTCAAGGC-3′
Reverse: 5′-CAGAGGGGCCGTCCACGGTCTTCTGGGTGG-3′
GZMB
Forward: 5′-ATCAAGTGTGGTGGGTTCCT-3′
Reverse: 5′-TGCTGGGTCTTCTCCTGTTC-3′
PRDM1
Forward: 5'-TTGCAAAGAAACATGGGGAATGGA-3'
Reverse: 5'-ACAGGCCCCAGAGGTAGTG-3'

TBX21
Forward: 5'-GTTCGTGGACGTGGTCTTG-3'
Reverse: 5'-GACGTACAGGCGGTTTCCT-3'

Primers were synthesized by Sigma-Aldrich. qRT-PCR assays were performed in
triplicate using cDNA generated from 2.5-8.3ng of RNA depending on the assay, SYBR
Green (ThermoFisher), and 100 nM primers. Assays were performed on an Applied
BioSystems 7500 Fast Real-Time PCR System device and analyzed using 7500 Fast
System Software version 1.4.0, or an Applied Biosystems ViiA7 device and analyzed
using QuantStudio RealTimePCR Software version 1.3 (Applied Biosystems, Carlsbad,
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CA). Dissociation curves were analyzed after each experiment to confirm the specificity
of product amplification.

RT-PCR
For samples taken from Patient 434-001, RT-PCR for the CAR was performed using
primers designed to anneal to non-homologous regions of human CD3ζ included in the
RNA CAR construct: Forward 5’-GTACCAGCAGGGCCAGAAC-3', Reverse 5’TCCTGAGGGTTCTTCCTTCTC-3”.
For CD19 RT-PCR, primers designed for cloning CD19 with a XhoI cut site were used:
Forward 5’-GGTTCCCTGGTGAGCTTTCT-3', Reverse 5’CTGCACTCGAGTTGACGCTGTCTGCTTAGGTT-3”.
1kb+ Ladder shown in gel images from Life Technologies.

Generation of anti-cCD20 and anti-hCD19 mRNA CAR vectors
The anti-cCD20 scFv was generated through a fusion of the heavy and light chains of the
variable fragments of a mouse-anti-human CD20 antibody, synthesized by Geneart (La
Jolla, CA) and cloned into a DNA plasmid by our collaborator, Dr. Colleen M.
O’Connor, while in the lab of Dr. Laurence Cooper (O'Connor et al., 2013). From this
plasmid, cCD20 scFv sequence was PCR-amplified using the following primers: cCD20
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scFv-Forward 5′-ACGCGGATCCGACATCGTGCTGTCCCAGAGCCCCGCCATC-3′
(BamHI) and cCD20 scFv-Reverse 5′ACGCGCTAGCGCTGGACACGGTCAGTGTGGTGCCCTGGCC-3′ (NheI). A DNA
plasmid containing the human, FMC63-based, hCD19-CD28-ζ CAR was used as a
template to amplify the hCD19 scFv using the following primers: CD19 scFv- Forward
5′- ACGCGGATCCGACATCCAGATGACACAGACTACATCCTCC-3′ (BamHI) and
CD19 scFv-Reverse 5′ACGCGCTAGCTGAGGAGACGGTGACTGAGGTTCCTTGGCC-3′
(NheI). Amplified sequences were gel purified, double digested with the indicated
restriction enzymes, and ligated into a BamHI and NheI-digested pD-A.lenti cloning
site.2bg.150A (PDA) vector backbone that contained the following human components:
CD8α leader, CD8α hinge, CD8α transmembrane domain, and a CD3ζ intracellular
signaling domain. Insertion of the scFv was confirmed by sequencing. RNA was
synthesized as previously described. Briefly, the cCD20-ζ CAR PDA plasmid was
linearized by digestion with SpeI. RNA in vitro transcription was then performed using
the T7 mScript Standard mRNA production system (CellScript, Madison, WI) as per the
manufacturer's instructions to obtain capped and tailed RNA. RNA vector was aliquoted
into single use vials and stored at –150°C until use.
Additional anti-human CD19-targeting scFv clones (21D4, 12B, and one derived from
blinatumomab) were provided by the lab of Dr. Michael Milone.
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RNA electroporation
Canine T cells were electroporated with mRNA vectors after 14–16 days post-stimulation
with the aAPC platform once T cells were rested down (<300 fL size, Coulter Count,
Beckman Coulter, Indianapolis, IN). Previously described methods for electroporation of
human T cells were used to guide testing of optimal conditions for canine T cells
(Schutsky et al., 2015). T cells were washed twice with cold Opti-MEM media (Gibco)
and resuspended at 108 cells/ml. Increasing voltages (range: 200–600 V) with constant
time (700 μs) and RNA (1 μg/106 cells), increasing time (700 μs, 1 ms) with constant
voltage (500 V) and RNA (1 μg/106 cells), and increasing RNA (0.1, 1, and 2
μg/106 cells) with constant voltage (500 V) and time (700 μs) were assessed. Optimal
conditions were similar to those previously described for human T cells (Schutsky et al.,
2015). Briefly, canine T cells were washed twice with cold Opti-MEM media (Gibco)
and resuspended at 108 cells/ml. 20 μg mRNA CAR vector and 2 × 107 cells (1
μg/106 cells) were electroporated in cuvettes (0.2 cm, Bio Rad, Hercules, CA) at 500 V
for 700 μs (Electro Square Porator, BTX Harvard Apparatus, Holliston, MA). Cells were
then cultured in TCM with rhIL-2 at 1–2 × 107cells/ml in multiple wells of 12-well plates
(BioExpress, Kaysville, UT).

Generation of lentivirus CAR vectors
The lentivector pELNS was kindly provided by Dr. Michael Milone. pELNS is a thirdgeneration, self-inactivating lentivector derived from pCLPS, with the EF-1α promoter in
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place of the CMV promoter and the insertion of an NheI cut site within the multiple
cloning site of the vector 5’ of the transgene. A point mutation within that NheI site was
generated using a compatible cohesive overhang from an SpeI-digested insert, resulting
in the NheI sequence GCTAGC within the multiple cloning site become GCTAGT,
allowing easier insertion and removal of scFvs within the vector; all CAR constructs
were inserted into this new vector, called pELxPS. Plasmids for CAR constructs, the
helper plasmids pCI VSV-G, pRSV Rev, and pMDL gag/pol.RRE, as well as all other
plasmids were maxiprepped using the Qiagen EndoFree plasmid purification kits
(Valencia, CA); later production of pELxPS cCD20-8-28-ζ, pELxPS cCD20-8-BB-ζ, and
pCI VSV-G plasmids was sourced to Nature Technology Corporation (Lincoln, NE).
Canine CD8α, CD28, 4-1BB, and CD3ζ components were originally cloned from canine
PBMC cDNA by Dr. Nicola J. Mason, and synthesized together using overlap extension
PCR with an anti-hCD19 (FMC63) scFv flanked with NheI sites as a stuffer and cloned
into pCLPS, and then later into pELxPS. cCD20-8-28ζ CAR construct was generated inhouse by digestion of the hCD19 scFv-containing CAR contruct within pELxPS and the
PCR amplified cCD20 scFv sequence with NheI and exchange of the scFvs; codonoptimized cCD20-8-BB-ζ construct sequence was synthesized from the determined
amino acid sequence by Genscript (Piscataway, NJ) and cloned into pELxPS by XbaI and
SalI digestion.
Lentivirus was produced through transient transfection of 293T cells using Lipofectamine
200 (Life Technologies) as previously described. Lentivirus-contained supernatants were
concentrated by centrifugation for at least 8 hours and at least 15,000g. Concentrated
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lentivirus titer was determined by limiting dilution infection of either bead-stimulated
primary human CD4+ T cells or Jurkat cells. Parallel infections of Jurkats and multiple
primary human CD4+ T cell donors showed a 2.9-fold increase in GFP transduction
efficiency and 5-fold increase in CAR transduction efficiency of Jurkat cells compared to
primary human CD4+ T cells. Titrations performed on Jurkat cells had the resulting
calculated titer converted back to primary CD4+ T cell equivalents when determining
MOI for canine T cell infection.

CAR T cell functional assays
All functional assays for RNA CAR T cells were performed 24 hours postelectroporation of mRNA CAR vectors; transfection efficiency was generally >90%.
For cytokine release assays, 106 T cells were co-cultured with 106 cell targets in 200 μl
TCM in triplicate wells. After 24 hours of co-culture, canine IFNγ production in cell-free
supernatants was assessed via ELISA (R&D Systems, Minneapolis, MN).
For chromium-release cytotoxicity assays, 104 chromium-labeled targets were plated in
sextuplicate in 96-well plates. T cells were added at the indicated E:T ratios. Co-cultures
were incubated for 4 hours at 37°C in phenol-free TCM. Specific lysis was measured
using a liquid scintillation counter (1450 Microbeta Plus, Long Island Scientific). Percent
lysis = 100 – ((experimental cpm – spontaneous cpm) / (maximum cpm – spontaneous
cpm wells)) × 100, where spontaneous is cpm of target cells with T cells electroporated
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without mRNA and maximum lysis is cpm of target cells with addition of 5% dimethyl
sulfoxide.
For luciferase-based cytotoxicity assays, a fixed number of irradiated target cells were
plated in 96-well plates. T cells were added at the indicated E:T ratios in triplicate, with
total T cell number as the Effector regardless of transduction efficiency. Co-cultures were
incubated for 24 hours at 37°C. Cultures were transferred to a 96-well V-bottom plate,
pelleted, and supernatant transferred to another 96-well plate and stored at -80°C for later
cytokine measurement. Cells washed twice with PBS, and then manufacturer’s
instructions were followed for the Luciferase Assay System (Promega, Madison, WI) and
measured on a luminometer. Percent lysis = 100 x (1 – (Experimental/Target Alone)),
percent specific lysis = 100 x (1 – (CAR Experimental/Non-transduced Experimental)).
For flow cytometry-based cytotoxicity assay, a fixed number of irradiated target cells
were plated in 96-well plates. T cells were added at the indicated E:T ratios in triplicate,
with total T cell number as the Effector regardless of transduction efficiency. Co-cultures
were incubated for 24 hours at 37°C. Cultures were transferred to a 96-well V-bottom
plate, pelleted, and supernatant transferred to another 96-well plate and stored at -80°C
for later cytokine measurement. Cells washed with FACS buffer, and stained for 7-AAD
and CD79a (if target cells did not express GFP). 10μL Countbright beads added to the
samples before collection on a FACS Canto II. The number of live target cells was
enumerated by back-calculating from the count of 7-AAD-, target marker positive events
and Countbright bead events in each tube. Percent lysis = 100 x (1 –
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(Experimental/Target Alone)), percent specific lysis = 100 x (1 – (CAR
Experimental/Non-transduced Experimental)).
For proliferation assays, T cells were assessed for CAR T cell expression and then equal
numbers of T cells and irradiated target cells were incubated at 37°C for the indicated
period of time. Live cells were then counted by trypan exclusion, and the number of CAR
T cells was enumerated using the frequency of CD5+CAR+ cells measured by flow
cytometry.

Ethics statement and regulatory approvals
These studies were approved by the University of Pennsylvania's Institutional Animal
Care and Use Committee (Protocol number 805496 for the mRNA CAR T cells in
Chapter 2, Protocol Number 805389 for the lentivirus CAR T cells in Chapter 3 and 4)
and signed owner consent was required prior to enrollment. The use of recombinant DNA
was approved by the University of Pennsylvania's Institutional Biosafety Committee
(IBC #14–103 for the mRNA CAR T cells in Chapter 2, and IBC#13-164 for the
lentivirus CAR T cells in Chapter 3 and 4).
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Eligibility criteria and study design
The purpose of the 434 study was to determine the safety and effectiveness of mRNAtransfected, autologous T cells expressing a cCD20-specific first-generation CAR against
B cell lymphoma. The purpose of the 429 study was to determine the safety and
effectiveness of lentivirally-transduced, autologous T cells expressing a cCD20-specific
second-generation CAR against B cell lymphoma. For the 434 mRNA study, dogs with a
histopathological and immunohistochemical diagnosis of B cell lymphoma that had
relapsed following a 25-week course of induction chemotherapy with a standard CHOPbased protocol (L-asparaginase, vincristine, cyclophosphamide, doxorubicin, and
prednisone) were eligible for screening. For the 429 lentivirus study, dogs with a
cytological diagnosis of B cell lymphoma that had relapsed following or during induction
chemotherapy (or dogs for which standard-of-care multi-agent induction chemotherapy
was not elected) were eligible for screening. In both studies, expression of cCD20 on
malignant lymphocytes was confirmed by flow cytometry, and patients were required to
have at least one measureable target lesion that could be repeatedly measured and
evaluated by either aspiration or biopsy. A thorough physical exam, complete blood
count, chemistry screen, and urinalysis were performed to determine general health status
for both studies. Thoracic radiographs and abdominal ultrasound were also performed to
determine extent of disease burden for both studies.
In both studies, dogs were pre-treated with diphenhydramine (2 mg/kg i.m.) and
ondansetron (0.2 mg/kg i.v.) prior to administration of CAR T cells. CAR T cells were
infused in 0.9% plasmalyte. Blood samples and lymph node aspirates were taken pre161

infusion and timepoints post-infusion indicated in the results, to characterize the T and B
cells and to assess presence of CAR T cells. Affected lymph nodes were measured by
caliper measurements and ultrasonographically pre-infusion and timepoints post-infusion
indicated in the results, with at least 2 perpendicular dimensions taken for each enlarged
lymph node. Lymph node volume was calculated as previous described (GaurnierHausser et al., 2011).

Cytokine bead array
Peripheral blood was collected in glass vacutainers (BD) and allowed to clot for 30
minutes before centrifugation at 1983g for 5 minutes. Serum was separated and stored at
–80°C prior to analysis. Samples were run in duplicate using the Canine Cytokine
Magnetic Bead Panel (Catalog No. PN CCYTOMAG-90K-PX13, EMD Millipore).
Calibration, data collection and verification were performed on the Luminex 200 using
xPONENT software according to the manufacturer's instructions. The data report was
generated using Millipore Analyst Software.

Detection of serum anti-mouse immunoglobulin antibodies
Serum samples, collected and stored as above, were analyzed by ELISA in triplicate
using a human-anti-mouse Ig Kit (Biolegend). Anti-mouse immunoglobulin antibody
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concentrations were calculated from standard dilutions fit to a 5-parameter curve and
validated by QC samples included in the kit.

qPCR for CAR Gene Quantification
qPCR for CAR gene performed by the University of Pennsylvania Translational and
Correlative Studies Laboratory. In brief, Taqman assays were performed on canine
genomic DNA samples for WPRE, a component of the lentivector backbone that is
integrated into the genome, and canine MC1R, a canine reference gene to normalize
genomic DNA input, alongside a plasmid standard curve to quantify integrated copies per
μg of canine genomic DNA.

Statistical analyses
Tests performed as described in results, using Prism software version 5.03 (Graphpad, La
Jolla, CA).
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